Hemoglobins with intersubunit desulfide bonds

ABSTRACT

Cysteine substitution mutants of alpha and/or beta globin mutants are produced by recombinant DNA techniques and used in the construction, intracellularly or otherwise, of mutant hemoglobins in which alpha- and beta-globin like subunits are crosslinked by disulfide bonds. Solutions of these mutant hemoglobins are used as blood substitutes. 
     Preferably, these mutant hemoglobins contain further mutations which reduce their affinity for oxygen. 
     Hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be readily expressed, making possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes. Expression of the alpha globin gene was substantially improved by means of a beta globin gene &#34;header&#34;.

This application is a continuation of application Ser. No. 07/443,950,filed Dec. 1, 1989, now abandoned, which is a continuation-in-part ofapplication Ser. No. 07/194,338, filed on May 10, 1988, now U.S. Pat.No. 5,028,588 issued on Jul. 2, 1991, all hereby incorporated byreference.

Priority is claimed under 35 U.S.C. 119 from U.K. Appl. 8711614, filedMay 16, 1987, and incorporated by referene herein.

BACKGROUND OF THE INVENTION

1. Field of Invention

This invention relates to novel hemoglobin compositions useful assubstitutes for red blood cells, and to methods of preparing same. Itfurther relates to the preparation, using recombinant DNA technology, ofmutant hemoglobins for use in such compositions.

2. Information Disclosure Statement

It is not always practical to transfuse a patient with donated blood. Inthese situations, use of a red blood cell substitute is necessary. Theproduct must effectively transport O₂, just as do red blood cells.("Non-hemoglobin Plasma expanders", such as dextran and albumin, do nottransport oxygen.) The two types of substitutes that have been studiedmost extensively are hemoglobin solutions and fluorocarbon emulsions.

Hemoglobin (Hgb) is the oxygen-carrying component of blood. Hemoglobincirculates through the bloodstream inside small enucleate cells callederythrocytes (red blood cells). Hemoglobin is a protein constructed fromfour associated polypeptide chains, and bearing prosthetic groups knownas hemes. The erythrocyte helps maintain hemoglobin in its reduced,functional form. The heme iron atom is liable to oxidation, but may bereduced again by one of two enzyme systems within the erythrocyte, thecytochrome b₅ and glutathione reduction systems.

Hemoglobin exhibits cooperative binding of oxygen by the four subunitsof the hemoglobin molecule (two alpha-globins and two beta-globins inthe case of Hgb A), and this cooperativity greatly facilitates efficientoxygen transport. Cooperativity, achieved by the socalled heme-hemeinteraction, allows hemoglobin to vary its affinity for oxygen.Hemoglobin reversibly binds up to four moles of oxygen per mole of Hgb.At high oxygen concentration, such as that found in the lungs, theoxygen affinity is high and hemoglobin is almost saturated with oxygen.At low oxygen concentration, such as that found in actively respiringtissue, the oxygen affinity is lowered and oxygen is unloaded.

Oxygen-carrying compounds are frequently compared by means of a deviceknown as an oxygen dissociation curve. This curve is obtained when, fora given oxygen carrier, oxygen saturation is graphed against the partialpressure of oxygen. The percentage of saturation increases with partialpressure according to a sigmoid relationship. The P₅₀ is the partialpressure at which the oxygen-carrying solution is half saturated withoxygen. It is thus a measure of oxygen-binding affinity; the higher theP₅₀, the more loosely the oxygen is held.

When the oxygen dissociation curve of a oxygen-carrying solution is suchthat the P₅₀ is less than that for whole blood, it is said to be"left-shifted."

The oxygen affinity of hemoglobin is lowered by the presence of2,3-diphosphoglycerate (2,3-DPG), chloride ions and hydrogen ions.Respiring tissue releases carbon dioxide into the blood and lowers itspH (i.e. increases the hydrogen ion concentration), thereby causingoxygen to dissociate from hemoglobin and allowing it to diffuse intoindividual cells.

The ability of hemoglobin to alter its oxygen affinity, increasing theefficiency of oxygen transport around the body, is dependent on thepresence of the metabolite 2,3-DPG. Inside the erythrocyte 2,3-DPG ispresent at a concentration nearly as great as that of hemoglobin itself.In the absence of 2,3-DPG "conventional" hemoglobin binds oxygen verytightly and would release little oxygen to respiring tissue.

Aging erythrocytes release small amounts of free hemoglobin into theblood plasma where it is rapidly bound by the scavenging proteinhaptoglobin. The hemoglobin-haptoglobin complex is removed from theblood and degraded by the spleen and liver.

It is clear from the above considerations that free native hemoglobin A,injected directly into the bloodstream, would not support efficientoxygen transport about the body. The essential allosteric regulator2,3-DPG is not present in sufficient concentration in the plasma toallow hemoglobin to release much oxygen at venous oxygen tension, andfree hemoglobin would be rapidly inactivated as an oxygen carrier byautooxidation of the heme iron.

Nonetheless, solutions of conventional hemoglobin have been used as RBCsubstitutes. The classic method of preparing hemoglobin solutionsemploys outdated blood. The red cells are lysed and cellular debris isremoved, leaving what is hopefully "stromal-free hemoglobin" (SFH).

Several basic problems have been observed with this approach. Thesolution must be freed of any toxic components of the red cell membranewithout resorting to cumbersome and tedious procedures which woulddiscourage large-scale production. DeVenuto, "Appraisal of HemoglobinSolution as a Blood Substitute", Surgery, Gynecology and Obstetrics,149:417-436 (1979).

Second, as expected, such solutions are "left-shifted" (lower P₅₀) ascompared to whole blood. Gould, et al., "The Development of PolymerizedPyridoxylated Hemoglobin Solution as a Red Cell Substitute", Ann Emerg.Med. 15: 1416-1419 (Dec. 1986).

Third, SFH has a half-life in the circulatory system of only about 2-4hours. This is because oxyHgb partially dissociates into a dimer that issmall enough to be filtered by the kidney.

Finally, SFH has a high colloid osmotic pressure (COD). Thus,administration of SFH in a dose that would have the same oxygen-carryingcapacity as a unit of packed red blood cells is inadvisable, since thehigh osmotic pressure (60 mm Hg) would cause a massive influx of waterfrom the cells into the bloodstream, thus dehydrating the patient'stissues. This consideration limits the dose of SFH to about 6-8 gmHgb/dl.

In an effort to restore the desired P₅₀, researchers added 2,3-DPG tothe hemoglobin solution. Unfortunately, 2,3-DPG was rapidly eliminatedfrom the circulation. Scientists then turned to other organicphosphates, particularly pyridoxal phosphate. Like 2,3-DPG, thesecompounds stabilized the "T state" of the Hgb by forming a salt bridgebetween the N-termini of the two beta chains. The pyridoxylatedhemoglobin had a P₅₀ of 20-22 torr, as compared to 10 torr for SFH and28 torr for whole blood. While this is an improvement over SFH, thepyridoxylated Hgb remains "high affinity" relative to whole blood.

Hemoglobin has been chemically modified (by intramolecular orintermolecular crosslinking) to increase intravascular retention andreduce osmotic pressure. Unfortunately, this polymerization also causesa "left shift" of the molecule's oxygen dissociation curve. Thus, forpolymerized-pyridoxylated Hgb, the P₅₀ is about 18 torr.

For chemical modifications of hemoglobin, See Iwashita, U.S. Pat. Nos.4,412,989 and 4,301,144 (with polyalkylene glycol), Iwasaki, U.S. Pat.No. 4,670,417 (with polyalkylene oxide), (with a polysaccharide);Nicolau, U.S. Pat. No. 4,321,259 and U.S. Pat. No. 4,473,563 (withinositol phosphate); Wong, U.S. Pat. Nos. 4,710,488 and 4,650,786 (withinositol phosphate and a polysaccharide); Bonhard, U.S. Pat. No.4,336,248 (with other proteins or gelatin derivatives); Walder, U.S.Pat. No. 4,598,064 and U.S. Pat. No. 4,600,531 (intramolecularlycrosslinked hemoglobin) and Ajisaka, U.S. Pat. No. 4,377,512 (withinulin).

The human alpha- and beta-globin genes have both been cloned andsequenced. Liebhaber, et al., P.N.A.S. (U.S.A.) 77:7054-58 (1980)(alpha-globin genomic DNA); Marotta, et al., J. Biol. Chem., 252:5040-53 (1977) (beta-globin cDNA).

Nagai and Thorgerson (Nature, 309: 810-812, 1984) expressed in E. coli ahybrid protein consisting of the 31 amino-terminal residues of thelambda cII protein, an Ile-Glu-Gly-Arg linker, and the complete humanbeta globin chain. They cleaved the hybrid at the single arginine withblood coagulation factor Xa, thus liberating the beta-globin chain.

Later, Nagai, et al., P.N.A.S. (U.S.A.), 82: 7252-55 (1985) took therDNA-derived human beta globin, naturally derived human alpha globin,and a source of heme and succeeded in producing active human hemoglobin.Additionally, they produced two semi-artificial analogues of thenaturally occurring mutant hemoglobins Hb Nympheas and Hb Daphne bysite-directed mutagenesis of the cloned beta-globin gene, expression ofthe modified gene, and combination of the rDNA-derived beta chain withnaturally occurring alpha chain and a source of heme. Like the naturallyoccurring mutants, these semiartificial analogues exhibited increasedoxygen affinity as compared to "normal" hemoglobin. In subsequentstudies, the structural basis for this change in oxygen binding wasestablished. Luisi and Nagai, Nature, 320: 555-56 (1986); and cp. Nagai,et al., Nature, 329:858-860 (Oct. 1987) (similar production of mutanthemoglobins with replacements of Val(67beta)E11).

Surprisingly, the expression of the human alpha globin gene inheterologous cells is substantially improved when this gene is fused toa portion of the beta globin gene.

SUMMARY OF THE INVENTION

We have discovered that the disadvantages of hemoglobin solutions asblood substitutes are overcome if a mutant hemoglobin species isselected which, in a typical cell-free blood substitute solution, wouldimpart to the solution a P₅₀ comparable to that of non-mutant hemoglobinin RBC-bound state. Naturally occurring hemoglobin mutants which, in theerythrocyte environment, would impart to the erythrocyte a P₅₀ higherthan the normal value for whole blood (28 torr) are of particularinterest, both in their own right and for what they teach about thestructural foundations of oxygen affinity. It is expected that many such"right-shifted" species, outside the erythrocyte environment (and thusthe right-shifting influence of 2,3-DPG), will assume a P₅₀ comparableto or greater than that of the normal P₅₀ for whole blood.

For the purposes of this invention, the term "conventional hemoglobin A"refers to the species of Hgb A whose alpha and beta chains are of theamino acid sequence given in FIG. 1. This is the species which is mostfrequently found in human erythrocytes and which imparts to sucherythrocytes a P₅₀ of about 28 torr. A "hemoglobin A mutant" is definedas any species of hemoglobin A whose alpha or beta chain is of an aminoacid sequence different from that set forth in FIG. 1. A "low affinity"hemoglobin A mutant is one which has a P₅₀ at least about 10% greaterthan that of "conventional hemoglobin A" in the same environment. It isparticularly desirable that its P₅₀ be at least that twice ofconventional (wild type) hemoglobin A in the absence of 2,3-DPG. A"recombinant" hemoglobin is one composed of an alpha and beta globin atleast one of which is obtained by expression of a globin gene carried bya recombinant DNA molecule, whether the hemoglobin is a conventionalhemoglobin or a mutant species.

A large number of naturally occurring low affinity Hgb A mutants areknown. (See Table I). The mutations may appear in either the alpha orthe beta chains of the molecule (or both, of course). Thus, HgbHazebrouck is a beta mutant (38(C4):thr→pro) whose P₅₀ is 36 (in wholeblood), declining to 27-29 torr in vitro.

Clearly, one cannot depend on nature to provide an adequate supply ofthese low affinity mutants. Consequently, the mutant polypeptide chainwill usually be prepared artificially, either by direct polypeptidesynthesis, or, more preferably, by in vivo expression of thecorresponding mutant gene in a suitable host cell. This gene may beobtained directly from the genome of the mutant erythrocyte precursor (amature erythrocyte does not contain DNA), as a complementary DNA (cDNA)transcribed from the messenger RNA of the mutant erythrocyte precursor,by direct polynucleotide synthesis, or, preferably, by in vitromutagenesis of the gene encoding conventional hemoglobin.

If one of the chains is identical to that of "conventional" hemoglobin,it may be obtained either naturally or synthetically. In addition, tocreate a functional hemoglobin molecule, it is necessary to provide theprosthetic heme groups and to couple the alpha and beta chains.

It is also within the contemplation of this invention to prepare and usenon-naturally occurring low affinity mutants by appropriate modificationand expression of the alpha or beta globin gene and subsequent assemblyof a recombinant hemoglobin. Methods for selecting candidate sequencesand evaluating their suitability for use in a blood substitute productare described herein.

We also have discovered that human alpha-globin may be obtained from abacterial host by (1) constructing a fused gene which comprises not onlythe alpha-globin gene but also at least a portion of the beta globingene, separated by spacer DNA encoding a selective protease cleavagesite; (2) expressing the fused gene in the form of a fusion protein; and(3) cleaving the fusion protein at the aforementioned cleavage site inorder to liberate the human alpha-globin. The use of the beta headerresults in about three-fold greater expression of the alpha globin.

As a result of this discovery, it is possible to prepare entirelyartificial human hemoglobin, that is, hemoglobin in which both the alphaand beta globin chains are formed in cells other than humanerythrocytes. Such fully artificial hemoglobin is ideal for use in bloodsubstitute and plasmic volume expander solutions. Of course,semi-artificial hemoglobins (one chain obtained from non-erythrocytesource) may still be used.

When extracted natural hemoglobin is used as a blood substitute, onemust be concerned with the toxicity of red blood cell membranecomponents which might contaminate the product. It is known thaterythrocyte stroma can cause dyspnea, bronchospasm, hypotension,arrythmia, disseminated intravascular coagulation, activation ofcomplement, and renal, myocardial and hepatic changes associated withischemia and acute inflammation. See Feola, Surgery, Gynecology &Obstetrics, 166:211-222 (March 1988); MacDonald, et al., F.A.S.E.B.J.,2(6) Abstr. 8217 (1988); Stone, et al., Surgery, Gynecology andObstetrics, 149:874-876 (1979); Rabiner, et al, J. Exp. Med., 126:1127-42 (1967). While purified preparations of natural hemoglobin areknown (so called "stroma-free hemoglobin"), Feola comments, "a trulypure hemoglobin solution has not been produced."

Another concern with natural hemoglobin is contamination with infectiousagents communicated by blood. Bove, Progr. Hematol., 14: 123-145 (1986)reported that hepatitis viruses, cytomegalovirus, Epstein-Barr virus,serum parvoviruses, syphilis, malaria, filariasis, trypanosomiasis,babesiosis, numerous pathogenic bacteria, and AIDS are all transmittedby blood transfusions. AIDS has even been transmitted by bloodtransfusions screened as negative for HIV antibody. Ward, et al., NewEngl. J. Med., 318: 473-78 (1988).

The alpha-globin-like polypeptide of the present invention may beidentical in sequence to natural normal human alpha-globin or to anaturally occurring hemoglobin mutant, or it may be an alpha-globinmutant which is not known in nature. It may be a tandem repeat of twoalpha globin-like sequences, see Ser. No. 07/374,161, now abandoned,incorporated by reference. The beta-globin-like polypeptide isanalogously defined.

A hemoglobin-like protein comprises at least one tetramer orpseudotetramer of two alpha globin-like subunits and two betaglobin-like subunits. An alpha globin-like subunit is a polypeptide, ora segment of a polypeptide having an amino acid sequence identical orsufficiently similar to alpha globin to incorporate heme and, after suchincorporation, cooperating with other globin-like subunits, as inhemoglobin, to reversibly bind oxygen. A beta globin subunit isanalogously defined.

Mutant hemoglobins, whether of reduced or enhanced oxygen affinity, arecapable of altering O₂ concentrations in cell cultures, or forextracting O₂ from fluids.

We have further discovered that cysteine substitution mutants of alphaand/or beta globin may be prepared, facilitating the preparation of amutant hemoglobin-like protein characterized by at least oneintersubunit disulfide bond. Such disulfide bonded forms are expected tohave the advantage of increased vascular retention. Since they arecrosslinked into the T state, it is expected that they will also beright-shifted, unlike the polymerized, pyrridoxylated hemoglobins knownin the art. Additional mutations may be introduced to reduce the oxygenaffinity further. Alternatively, if the crosslinking reduces the oxygenaffinity too much, additional mutations may be made to correct theoxygen affinity.

The appended claims are hereby incorporated by reference into thisspecification as a statement of the preferred embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the amino acid sequence of the (a) alpha (FIG. 1A) and (b)beta (FIG. 1B) chains of conventional human hemoglobin A, and thenucleotide sequences encoding these chains.

FIG. 2 shows selected DNA sequences and enzyme restriction maps of (a)M13 mp11 FX (FIG. 2A), (b) pLcIIFX beta, (FIG. 2B) and pLcII beta (FIB.2B), and (c) pLCIIFX-beta-FX-alpha (FIG. 2C). Note that pLCIIFX alpha(FIG. 2D) lacks the codon encoding beta His 2 in FIG. 2(b).

FIG. 3 shows equilibrium oxygen binding curves for artificialconventional human hemoglobin (open boxes) and mutant human hemoglobinhaving the structure of Hgb Kansas (α₂ β₂ Asn¹⁰² →Thr)(shaded boxes).0.1 m HEPES, ph 7.4, 0.1M NaCl, 25 C°.

DETAILED DESCRIPTION OF THE INVENTION

One aspect of this invention is the cloning and expression of anexogenous alpha globin gene in a suitable host. The host may be aprocaryotic cell (such as a E. coli) or a eucaryotic cell (such as ayeast cell or a mammalian cell). The alpha globin gene will usually codeon expression for a polypeptide corresponding to a naturally occurringhuman alpha globin, normal or abnormal, but may correspond to a nonhumanalpha globin, or indeed be a non-naturally occurring analogue of knownalpha globins. Preferably, a mutant alpha globin is prepared andassembled into a low affinity hemoglobin mutant for use in a bloodsubstitute composition.

The alpha globin gene is expressed as part of a fused gene which alsocodes on expression for at least a portion of the beta globin gene. In apreferred embodiment, the alpha and beta globin sequences are separatedby spacer DNA encoding a selective protease cleavage site, inparticular, a site susceptible to specific cleavage by Factor Xa.

Preferably, the aforementioned fused gene includes a subsequence whichcodes on expression for the 20 amino acid N-terminal of beta globin.

As previously noted, the alpha globin of the present invention isadvantageously combined with rDNA-derived beta globin and a source ofheme to obtain fully artificial (derived entirely from sources otherthan blood) hemoglobin. Such hemoglobins, and especially low oxygenaffinity hemoglobin mutants produced through use of selectively modifiedalpha and/or beta globin genes, are of value as blood substitutes.Semi-artificial hemoglobins, in which the only chain obtained from anonerythrocyte source is a mutant sequence and the mutation impartsreduced oxygen affinity to the molecule, are also encompassed by thepresent invention and may also be used as blood substitutes. Unlessotherwise indicated, the term "artificial" embraces both wholly andsemiartificial forms.

In order to appreciate possible strategies for designing low affinityalpha or beta mutants of hemoglobin for use as blood substitutes, it isnecessary to understand the structure of the hemoglobin molecule.

The structure of conventional hemoglobin is well known. We herewithincorporate by reference the entire text of Bunn and Forget, eds.,Hemoglobin: Molecular, Genetic and Clinical Aspects (W. B. Saunders Co.,Philadelphia, Pa.: 1986) and of Fermi and Perutz "Hemoglobin andMyoglobin," in Phillips and Richards, Atlas of Molecular Structures inBiology (Clarendon Press: 1981).

The primary structure of a polypeptide is defined by its amino acidsequence and by identification of any modifications of the side chainsof the individual amino acids.

About 92% of the normal adult human hemolysate is Hgb A (designatedalpha2 beta2, because it comprises two alpha and two beta chains). Thealpha chain consists of 141 amino acids (See FIG. 1). The iron atom ofthe heme (ferroprotoporphyrin IX) group is bound covalently to theimidazole of his 87 (the "proximal histidine"). The beta chain is 146residues long (see FIG. 1) and heme is bound to it at His 92.

Other recognized hemoglobin species are Hgb A₂, Hgb A_(1a), Hgb A_(1b),and Hgb A_(1c), as well as the rare species Hgb F, Hgb F₁, Hgb Gower-1,Hgb Gower-2, Hgb Portland, Hgb H, and Hgb Bart. They are distinguishedfrom Hgb A by a different selection of polypeptide chains.

Segments of polypeptide chains may be stabilized by folding into one oftwo common conformations, the alpha helix and the beta pleated sheet. Inits native state, about 75% of the hemoglobin molecule is alpha-helical.Alpha-helical segments are separated by segments wherein the chain isless constrained. It is conventional to identify the alpha-helicalsegments of the each chain by letters, e.g., the proximal histidine ofthe alpha chain is F8 (residue 8 of helix F). The non-helical segmentsare identified by letter pairs, indicating which helical segments theyconnect. Thus, nonhelical segment BC lies between helix B and helix C.In comparing two variants of a particular hemoglobin chain, it may beenlightening to attempt to align the helical segments when seeking tofind structural homologies. For the amino acid sequence and helicalresidue notation for conventional human hemoglobin A_(o) alpha and betachains, see Table 4.

The tertiary structure of the hemoglobin molecule refers to the stericrelationships of amino acid residues that are far apart in the linearsequence, while quaternary structure refers to the way in which thesubunits (chains) are packed together. The tertiary and quaternarystructure of the hemoglobin molecule have been discerned by X-raydiffraction analysis of hemoglobin crystals, which allows one tocalculate the three-dimensional positions of the very atoms of themolecule.

In its unoxygenated ("deoxy", or "T" for "tense") form, the subunits ofhemoglobin (alpha1, alpha2, beta1, and beta2) form a tetrahedron havinga twofold axis of symmetry. The axis runs down a water-filled "centralcavity". The subunits interact with one another by means of Van derWaals forces and hydrogen bonds (and, in the case of deoxyhemoglobin, by"salt bridges"). The alpha1beta1 and alpha2beta2 interfaces remainrelatively fixed during oxygenation. In contrast, there is considerableflux at the alpha1beta2 (and alpha2beta1) interface. In its oxygenated("oxy", or "R" for "relaxed" form), the intersubunit distances areincreased.

The deoxy conformation is stabilized by numerous interactions,including, for example, the hydrogen bond between Tyr42alpha andAsp99beta. In the oxygenated form, this bond is broken and a new oneformed between Asp94alpha and Asn102beta.

Various different approaches to modification of hemoglobin may beadopted. In each case, a candidate mutant is selected which, on thebasis of the available evidence, is believed to be likely to have alower affinity for oxygen than conventional hemoglobin.

In making this selection, it is possible to consider not only the knowneffects of various mutations of human hemoglobin, but also the oxygenbinding capacity of known forms of animal hemoglobins, and of relatedcompounds such as carboxyhemoglobin, methemoglobin, myoglobin, etc.

Alpha Chain Mutants

Thanks to our success in overcoming the problems of expressing the alphaglobin gene in a heterologous system, it is now possible to convenientlyprepare alpha globin mutants.

Several low oxygen affinity hemoglobin alpha chain mutants are alreadyknown. Of these, Hb Titusville (alpha94Asp=→Asn), Hb Setif(alpha94Asp→Tyr), Hb Torino (alpha43Phe→Val), Hb Hirosaki(alpha43Phe→Leu) and Hb Moabit (alpha86Leu→Arg) are of special interest.

Alpha globins are more readily oxidized than beta globins because theHis(FS) to O₂ bond on the alpha chain is slightly stronger than on beta,so that an electron is more readily lost by the oxygen. Alpha globinscould be modified to make them less oxidizable, for example, by thechange alpha63His→Gln or Val.

Chloride ion binds to the alpha chain by bridging between the N-terminalNH₃ ⁺ and the hydroxyl of alpha131Ser. The effect of chloride binding isto increase the P₅₀ slightly. It is believed that by changing alpha131to Glu, Asp or Asn one could achieve the same effect without resortingto chloride. Alternatively, the pK_(a) of the N-terminal could beincreased. The natural human N-terminal is valine, with a pK_(a) of9.72. This could be replaced with Ile (9.76), Pro (10.60) or Thr(10.43).

Beta globin mutants, and additional alpha globin mutants which arelikely to impart reduced oxygen affinity, are discussed below.

Stabilizing the T state

It is not possible to raise the plasma concentration of 2,3-DPGsufficiently to maximize the oxygen carrying efficiency of freeconventional hemoglobin in the blood. This problem can be overcome bystabilizing the T state with additional salt-bridges or hydrogen bondsintroduced by protein engineering. The cross-linking of hemoglobin mayitself stabilize the T structure to some extent.

Hydrogen bonds and ionic salt bridges are the predominant stabilizingforces on the surface of proteins. Hydrogen bonds are weak non-ionicbonds formed between electronegative atoms (e.g. oxygen, nitrogen,sulfur) and protons that are covalently attached to otherelectronegative atoms. Individually, hydrogen bonds are weak (e.g. -1kcal/mol), but in a protein there are hundreds to thousands of hydrogenbonds that collectively amount to a large stabilizing force. An exampleof an hydrogen bond that is important to hemoglobin structure is thehydrogen bond formed between alpha-asp⁹⁴ and beta-asn¹⁰² in theoxy-state. When either of these residues is mutated to a residue thatcan no longer form this hydrogen bond the oxy state is destabilized andthe molecule has a much lower O₂ affinity. Hg Kansas (beta thr¹⁰²), HgBeth Israel (beta ser¹⁰²), Hg Richmond (beta lys¹⁰²), Hg St. Mande (betatyr¹⁰²), Hg Titusville (alpha asn⁹⁴) and Hg Setif (alpha tyr¹⁰²) are allexamples of the importance of this hydrogen bond. Other likelynonnatural mutants that will achieve the same effect are beta asp¹⁰²,beta glu¹⁰², beta arg¹⁰², beta his¹⁰², beta gly¹⁰² and beta cys¹⁰² ;alpha gln⁹⁴ , alpha thr⁹⁴ , alpha ser⁹⁴ , alpha lys⁹⁴, alpha gly⁹⁴ andalpha arg⁹⁴.

Ionic interactions are salt forms formed between juxtaposed residues ofopposite charge. These interactions are of much greater strength molefor mole than hydrogen bonds. An example of attraction of unlike chargeswould be the interaction between a lys and asp residue; at physiologicpH both of these residues are charged (positive and negative,respectively). Repulsion of two juxtaposed positive charges or twojuxtaposed negative charges may also occur; interactions such as theseare destabilizing.

Stabilization of the deoxy state of Hg by 2,3-DPG is an example of ionicinteraction. The 2,3-DPG molecule is highly charged at neutral pH (5negative charges) and interacts with eight residues in the 2,3-DPGpocket that are positively charged. It is felt that by engineering morepositive charge into this binding pocket that 2,3-DPG would bind moretightly to the engineered Hgb than to HgbA. Another example is thealpha₁ /beta₂ interface where alpha asp⁹⁴ hydrogen bonds to beta asn¹⁰².Replacing beta asn¹⁰² with a negatively charged group such as asp or gluwill interfere with oxy state stabilization by charge repulsion with thelike charged alpha asp⁹⁴.

Thus, certain amino acid residue changes can facilitate the formation ofthe desired hydrogen bonds and salt bridges.

The T conformation can also be stabilized by the substitution ofcysteine residues for other residues. Cysteine residues may becross-linked by disulfide bonds. Examination of the published x-ray dataof methemoglobin suggests that the alpha₁ /beta₂ interface would be alogical place to put the disulfide. Further guidance about where toplace disulfides may be provided by Thornton, J. M. J. Mol. Biol. 151,261-287, 1981. Oxidation of cysteines to carry disulfide bonds(Cystines) can be carried out by treatment with O₂ or catalyzed bythioredoxin (Pigiet, V Am. Biotech. Lab 6, 48-52, 1988).

It is not necessary that one of the cysteine residues used to form thedisulfide bond be native to conventional hemoglobin. The followingpaired alpha and beta chain sites, located at the alpha₁ /beta₂interface, illustrate how both chains can be mutated to promotedisulfide bond formation:

i) Codon 41alpha Thr(ACC) →Cys(TGC) Codon 99beta Asp (GAC) →Cys (TGC)

ii) Codon 44alpha Pro (CCG) →Cys (TGC) Codon 97beta His (CAC) →Cys (TGC)

iii) Codon 94alpha Asp (GAT) →Cys (TGC) Codon 101beta Glu (GAA) →Cys(TGC)

iv) Codon 41alpha Thr (ACC) →Cys (TGC) Codon 97beta His (CAC) →Cys (TGC)

v) Codon 92alpha Arg (CGT) →Cys (TGC) Codon 37beta Trp (CAC) →Cys (TGC)

vi) Codon 92alpha Arg(CGT) →Cys(TGC) Codon 40beta Arg(CGT) →Cys(TGC)

vii) Codon 96alpha Val(GTT) →Cys(TGC) Codon 101beta Glu (GAA) →Cys (TGC)

Modifying residues near the oxygen binding site

Heme (haem) is the prosthetic group of hemoglobin, myoglobin, catalase,peroxidase, and cytochrome b. The heme is inserted in a cleft betweenthe E and F helices. The heme iron is linked covalently to the imidazolenitrogen of the "proximal" F8 histidine. The "distal" E11 valine appearsto guard the access of oxygen to the heme pocket.

Val-E11 and His-E7 are highly conserved residues which are in Van derWaals contact with the oxygen molecule liganded to the heme iron atomsof hemoglobin; by replacing these residues the intrinsic oxygen affinityof hemoglobin can be altered. Val-E11 has been replaced with Ile, Leu,Ala and Met. The oxygen affinity of the Ala-E11beta mutant was higherthan that of HbA; that of the Ile-E11beta mutant was lower. X-raycrystallographic study of the latter mutant showed that the delta-methylgroup of the Ile side chain must be pushed to one side if oxygen is tobind to the iron atom.

Another alteration that we have made is beta His63→Phe. This mutant hasan extraordinarily low oxygen affinity (See Table 3).

It has therefore been shown that the oxygen affinity of hemoglobin canbe altered at will by replacing residues close to the oxygen bindingsite. By adjusting oxygen affinity in this way the efficiency of oxygentransport can be maximized in the absence of allosteric effectors suchas 2,3-DPG.

The following residues of human deoxyhemoglobin are, on a nearestatom-to-nearest atom basis, within 4 angstroms of the heine moiety:Alpha B13(D)Met, C7(E)Tyr, CE1(D) Phe, CE3(E)His, CE4(D)Phe, E7(D)His,E10(D)Lys, E11(D)Val, E14(D)Ala, F4(P)Leu, F7(P)Leu, F8(P)His,FG3(P)Leu, FG5(P)Val, G4(P)Asn, G5(P)Phe, G8(D)Leu, H15(P)Val andH19(P)Leu; and Beta B13(D)Leu, C7(E)Phe, CD1(D)Phe, CD3(E)His,CD4(D)Phe, E7(D)His, E10(D)Lys, E11(D)Val, E14(D)Ala, F4(P)Leu, F7(P)Leu, F8(P)His, FG3(P) Leu, FG5(P)Val, G4(P)Asn, G5(P)Phe, G8(D) Leu,H15(P)Val, and H19(P) Leu. See Fermi, et al., J. Mol. Biol., 175:159-174 (1984). (In the above list, "P" denotes "proximal", "D","distal", and "E", "edge-on".)

These residues are therefore candidates for modification. Considerationshould also be given to pairs contacted through bound water molecules.See Ladner, et al., Mol. Biol., 114: 385-414 (1977).

Mutations of beta residues 42 (CD1), 45 (CD4) and 70 (E14) are ofparticular interest. Other beta residues of interest include 43 (CE1),46 (CE4), 58 (E7), 61 (E10) and 62 (E11). Alpha residues of interestinclude 43 (CE1), 46 (CE4), 58 (E7), 61 (E10) and 62 (E11).

^(I) n general, mutations around the heme-O₂ binding site that interferewith O₂ binding are also desirable because of their low-affinity O₂binding nature. Replacing residues that are adjacent to the face of hemethat binds O₂ can result in lower affinity. A naturally occurring mutantHg Bristol (beta⁶⁷ val→asp) has been described with low affinity. Othermutants that are desirable are the beta ile⁶⁷ described herein, betaasp⁶⁷ and beta glu⁶⁷. Other residues are also in the vicinity of the O₂binding site. Histidine E7 (beta his⁶³) can be replaced with phe whichresults in very low O₂ affinity. The other likely residue for mutationis beta phe⁴² ; replacement with trp is likely to result in low O₂affinity. The corresponding residues of the alpha chain may be alteredinstead of, or in addition to, these preferred mutations of the betachain.

Replacing residues at the alpha₁ beta₂ contact and the central cavity.

The oxygen affinity and cooperativity of hemoglobin depend on therelative stabilities of the T (low affinity) and R (high affinity)quaternary states. These two states are in equilibrium with each otherbut one state may be favored by mutations at the alpha₁ beta₂ contact orin the central cavity. There are many naturally occurring mutations atthese sites, and careful study of these should be of value in designinga hemoglobin molecule with the desired properties.

Thus alpha 1 residues 37 (C2) Pro, 38 (C3)Thr, 40(C5)Lys, 41(C6)Thr,42(C7)Tyr, 44(CD2)Pro, 88(F9)Ala, 91(FG3)Leu, 92(FG4)Arg, 94(G1)Asp,95(G2)Pro, 96(G3)Val, 97(G4)Asn, 140(HC2)Tyr, and 141(HC3)Arg are allknown to lie within 4 angstroms of at least one residue of the beta2chain of human deoxyhemoglobin. Similarly, beta2 residues 146(HC3)His,145(HC2)Tyr, 105(G7)Leu, 102(G4)Asn, 101(G3)Glu, 100(G2)Pro, 99(G1)Asp,98(FG5)Val, 97(FG4)His, 43(CD2)Glu, 41(C7)Phe, 40(C6)Arg, 37(C3)Trp,36(C2)Pro, 35(C1)Tyr, and 34(B16)Val lie on the other side of thealpha1beta2 interface of human deoxyhemoglobin.

Mutation of beta102(G4)Asn is particularly preferred. Hg Kansas is aknown low affinity mutant in which this residue is altered to Thr. Aspreviously mentioned, the oxy state is stabilized by a hydrogen bondbetween beta Asn102 and alpha Asp94. The preferred mutation woulddisrupt this hydrogen bond.

Another favored mutation at this site is to beta Asp102. The negativecharge-negative charge repulsion between this group and the alpha Asp94would further destabilize the oxy state.

Still other preferred mutations at the beta102 locus would be to Ser (HbBeth Israel), Lys (Hb Richmond) and Tyr (Hb St. Mande).

Increasing the stability of hemoglobin

Inside the erythrocyte the cytochrome b₅ and glutathione reductionsystems serve to maintain hemoglobin in the active ferrous form. Freehemoglobin in the bloodstream would rapidly be at least partiallyoxidized to the ferric state since there is no such means of keeping itin the reduced form outside the red cell. It is possible to stabilizethe ferrous formby replacing the Val-E11 residue with a large aliphaticamino acid such as Ile or Leu. A large side chain at this positionprevents electron donors from reaching the iron atom and so slows therate of autoxidation. The His63→Phe mutant is also of interest.

If hemoglobin is cross-linked both intermolecularly to form highermolecular weight aggregates and intramolecularly to prevent dissociationinto dimmers then it will neither react with haptoglobin nor passthrough the glomerular membrane of the kidney. If the oxygen bindingproperties of haemoglobin are to be unaffected it is important that thecross-linking does not prevent conformational change of the protein.This is because the heme-heme interaction arises from a reversibletransition between two quaternary structures: the T structure with lowoxygen affinity. These two structures with high oxygen affinity. Thesetwo structures differ in the contact between the alpha₁ and beta₂subunits. Therefore this contact should be allowed to undergo theconformational changes accompanying oxygen association and dissociation.

Site-directed mutagenesis can be used to replace certain surfaceresidues of haemoglobin with cysteinyl residues. Protein engineeringtechniques similar to those used to introduce new disulfide bridges tolysozyme, subtilisin and dihydrofolate reductase can be used. Hemoglobinmolecules carrying such --SH groups can be cross-linked by disulfidebridges or via a bifunctional thiol reagent. It should also be notedthat there is a natural mutant (Hb Ranier) in which His 143 beta isreplaced by Cys and the newly introduced cysteine forms a disulfidebridge with Cys 93 beta in vivo. This mutant is more stable than nativeHb.

Table 2 is a list of candidate, non-naturally occurring hemoglobinswhich are expected to exhibit a lower affinity for oxygen than doesconventional hemoglobin.

After determining the amino acid sequence changes which distinguish thedesired hemoglobin from conventional hemoglobin, it is necessary todesign the expression vector. The most convenient starting point is anucleotide sequence which codes upon expression for conventionalhemoglobin. This sequence then may be modified by site-specificmutagenesis.

Techniques of site-specific mutagenesis are well known, and thisinvention is not limited to any particular technique. The two principaltechniques are the gapped duplex A. A., Kruse, K. B., Brown, J. L.BioTechniques 6, 338-339, 1988) and M-13 (Zoller, M. J. and Smith, M.Meth. Enz. 100, 468-500, 1987) methods.

Alternatively, a subsequence with the desired mutation may besynthesized and then ligated to other subsequences to form the desiredmolecule.

The gene must be placed under the control of a promoter. Either aconstitutive or an inducible promoter may be used; the advantages anddisadvantages of each are well known in the molecular biology art. Apromoter must be chosen which is functional in the host. Thus, abacterial promoter would be chosen if the expression vector is to beintroduced into a bacterial host, a yeast promoter, if a yeast host, anda mammalian promoter, if a mammalian cell host. It should be understoodthat the promoter of a viral gene of a virus which infects the chosenhost cell may also be used. The present invention does not depend uponthe choice of either the promoter or the host. However, it is desirableto choose a host so that the subsequent purification of the mutanthemoglobin is not unduly complicated.

For the same reason, it is preferable, but not required, that the mutanthemoglobin be expressed as a moiety of a fusion protein. Attempts toexpress the alpha chain other than as a fusion protein were largelyunsuccessful. However, the entire alpha chain sequence could beexpressed as part of a fusion protein including a portion of the betachain, and separated from the latter by a spacer providing a selectivecleavage site. The hemoglobin is obtained merely by placing the secretedfusion protein in an appropriate cleavage environment. Numerous fusionprotein/cleavage system combinations are now known in the art.

After expressing, recovering and purifying the mutant hemoglobin, itsP₅₀ is measured in accordance with the protocol set forth in theReference Example. Preferably, its P₅₀ is at least 10% higher than thatof conventional hemoglobin A when measured in the same environment.

While it is not practical to combine stroma-free conventional hemoglobinwith sufficient 2,3-DPG to restore its P₅₀ to intra-erythrocyte levels,it may be possible to combine a modestly right-shifted mutant hemoglobinwith a small amount of 2,3-DPG or functionally similar organic phosphate(e.g., pyridoxal phosphate or ATP-dialdehyde) so as to mimic theoxygen-carrying capacity of whole blood. The half life of the organicphosphate may be improved by encapsulating the organic phosphate and themutant hemoglobin in a liposome to obtain a "simulated erythrocyte," orby covalently attaching the organic phosphate group to the hemoglobin.

Reference Example

Our preferred method of measuring the P₅₀ of purified hemogoblinsolutions for the purpose of the appended claims is as follows.

Hemoglobin-oxygen equilibrium data are measured using a thin filmtechnique (Imai, K. Meth. Enz. 76, 438-449, 1981). A sample ofhemoglobin (0.6 mM) in buffer (50 mM Bis-Tris or 100 mM HEPES), pH 7.4,0.1M NaCl, is applied to the cell and then equilibrated at 25° C. Thehemoglobin is saturated with O₂ by a stream of air, or air/O₂ if thehemoglobin has low O₂ affinity or if the local barometric pressureprevents abient oxygen from achieving a high enough partial pressure tosaturate the molecule. Deoxygenation is achieved by closing the cell toO₂ flow and flushing the cell with N₂ (>99.98% pure). The oxygenequilibrium curve is obtained by plotting the change in absorbance at560 nm against the pressure of O₂ in the cell. Percent saturation isdetermined by measuring the A⁵⁶⁰ at a given partial pressure (i) dividedby the A⁵⁶⁰ of the beginning, totally saturated Hgb solution Hgbsolution [A⁵⁶⁰ (i)/A⁵⁶⁰ (100%)×100 =% saturation]. The P₅₀ is defined asthe partial pressure (i) of O₂ required to cause 50% saturation of O₂binding sites.

P₅₀ may also be measured under other conditions, but it should be notedthat many environmental factors affect hemoglobin's oxygen affinity. Theeffect of Ph, CO₂, inorganic anions, organic phosphates and temperatureon P₅₀ are discussed in Bunn and Forget, HEMOGLOBIN:MOLECULAR, GENETICAND CLINICAL ASPECTS 37-47, 95-98 (W. B. Saunders Co.: 1986).

Since many determinations of whole blood oxygen binding curves are madeunder standard physiologic conditions (37° C., pH=7.4, PCO₂ =40 mm Hg),it may be necessary to adjust literature figures. In this context, itshould be noted that a 10° C. increase results in nearly a two-foldincrease in P₅₀, while the dependence of P₅₀, while the dependence ofP₅₀ on pH is approximately given as delta log P₅₀ /delta pH=-0.5.

Comparing P₅₀ values of purified Hb preparation to P₅₀ values of wholeblood can be problematic. Whole blood, or isolated RBC's, contain manycomponents that naturally modulate the shape of the hemoglobin-oxygenbinding curve. The RBC encapsulates Hgb in the presence of a highconcentration of the effector molecule 2,3-DPG; a molecule that causesHgb to have a markedly lower affinity for O₂. Other intra-erythrocytecomponents also affect the shape of the binding curve: ATP, Cl⁻, CO₂,H⁺, orthophosphate, methemoglobin and carboxyhemoglobin. Thesesubstances are not normally present in purified HgB solutions and thus,the P₅₀ value of purified Hgb is lower than that found in whole blood.One very important modulator of Hgb-oxygen affinity is Cl⁻ ion. Cl⁻ ionis found outside the erythrocyte in the blood serum at a physiologicconcentration of approximately 0.15M. Since Cl⁻ causes a lower O₂affinity, a Hgb solution with a P₅₀ measured in vitro may well have muchlower O₂ affinity if infused into the blood stream. Another problem withmeasuring O₂ binding of whole blood is that RBCs are quite fragile andin the process of manipulating the erythrocyte into the instrument usedto measure the O₂ binding it is inevitable that at least a smallpercentage of the RBCs will lyse. Lysed RBCs leak Hgb into thesurrounding media away from 2,3-DPG; hence, since free Hgb has a higheraffinity than intraerythrocyte Hgb, lysed RBCs will have a higher O₂affinity and can cause a falsely low P₅₀ value for whole blood P₅₀determinations. It is widely accepted that under physiologic conditionswhole blood has a P₅₀ value of 26-28 mmHg. When Hgb is isolated fromwhole blood, however, the measured P₅₀ is on the order of 1-10 mmHgdepending on the investigators experimental conditions. For thesereasons it is most accurate to measure Hgb-oxygen equilibria withpurified Hgb molecules under strict conditions of buffer, pH and saltconcentration. Unfortunately, there are no accepted "standards" for allinvestigators to measure Hgb oxygen binding in in vitro systems.

Still, as many mutant hemoglobins are first identified in patient'swhole blood, one would like to be able to compare the relativeaffinities of native and mutant Hgb for O₂, between whole blood andpurified Hgb preparations. An example of this is Hgb Chico (betalys.sup.Δ →thr) (Table 1). If one examined only the P₅₀ value of thepurified mutant Hgb (10.1 mmHg) one would note that Hgb has a P₅₀ valueless than that for normal whole blood (27.2 mmHg). Still, when thathemoglobin is measured in RBCs under physiologic conditions it isapparent that it does have a higher P₅₀ than normal whole blood (38 mmHg). One cannot predict the degree that the P₅₀ value will change goingfrom whole blood Chico to a purified Hgb Chico if it were infused intothe bloodstream as a blood substitute. One can conclude, however, thatthe P₅₀ will be higher than it is in pure form, and that by reacting themutant Hgb with organic phosphates that P₅₀ will be even higher.

Note also that whole blood oxygen binding curves are customarilydetermined under standard physiologic conditions (37° C., pH 7.4, PCO₂=40 mmHg) and red cell 2 3-PDG varies with age, sex and condition.

(Example 1: Production of Artificial Conventional Hemoglobins)Construction of M13 mp11 FX

M13 mp11 FX encodes a sequence (Ile-Glu-Gly-Arg) including therecognition site for factor X_(a). This M13 derivative can be used tojoin any coding sequence to the factor X_(a) recognition sequence. SeeNagai, EP Appl 161,937 (CELLTECH LTD.) However, this invention is notlimited to the use of either M13 or of the factor Xa cleavage system.

All DNA manipulations were carried out essentially as described byManiatis et al (`Molecular Cloning` Cold Spring Harbour, N.Y., 1982). Atemperature-sensitive lysogenic strain MZ-1 (galK_(am) 8attL BamN₇ N₅₃cI857 H1, his-, ilv-, bio-, N⁺, a gift from Dr. K. McKenney andavailable on request from Medical Research Council) was used as a hoststrain for plasmids containing lambda P_(L) promoter and transformationwas carried out by the method of Remaut et al (Gene 15, 81-93 (1981)).Other promoters and host strains could have been employed.

T4 DNA ligase was prepared from strain NM989 (Murray et al, J Molec Biol132, 493-505 (1979) and Tait et al, J Biol Chem 255, 813-815 (1980)).Restriction enzymes were purchased from New England BioLabs.

Two oligonucleotides dTACCCTCGATGGATC and dCATCGAGGGTAGGCC weresynthesized by a phosphotriester method on a controlled pore glasssupport (Sproat et al, Tetrahedron Lett, 24, 5771-5774 (1983)) andpurified by HPLC (Gait et al, Nucleic Acids Research 10, 6243-6254(1982)). These oligonucleotides encode the peptide sequence(gly)-ser-ile-glu-gly-arg in a BamHl-Stul linker. The twooligonucleotides were allowed to anneal after phosphorylation with T4polynucleotide kinase (P-L, Biochemicals) and r[gamma-³² P]ATP (3000Ci/m mol, Amersham) and ligated to form concatamers. The DNA was thendigested with Bam HI and cloned into the dephosphorylated Bam HI site ofM13 mp11 (Vieira et al, Gene 19, 259-268 (1982)) to yield M13 mp11 FX,as shown in FIG. 1a, which forms blue plaques in the presence ofisopropyl-beta-D-thiogalacto-pyranoside and5-bromo-4-chloro-3-indolyl-beta-d-galactoside (Sigma).

Construction of mp11 FX alpha-globin

40 micro g of cloned human alpha-globin cDNA were digested with therestriction enzymes Nco I and Apa I. The single-stranded ends of theexcised alpha-globin fragment were trimmed by incubation at 0° C. for 10minutes with 200 units of mung bean nuclease (P-L Biochemicals) in 30 mMsodium acetate pH 4.6, 50 mM sodium chloride, 1 mM zinc chloride, 5%glycerol. The alpha-globin sequence was then cloned into the Stu I siteof M13 mp11 FX described above (Nagai & Thogersen, Nature 309, 810-812).The DNA sequences of several clones were determined (Sanger et al Proc.Natl. Acad. Sci. USA, 74, 5463-5467 (1977)) and a clone in which thefirst valine codon of the alpha-globin gene was joined to the DNAsequence encoding the factor X_(a) recognition site (Ile-Glu-Gly-Arg)was named mp11 FX alpha-globin.

Construction of pLcII beta and pLcIIFX beta

Plasmids pLcIIFX beta and pLcII beta direct efficient production of ahybrid protein consisting of the 31 amino-terminal residues of thelambda CII protein and the complete human beta-globin, with and withoutthe factor X_(a) cleavage site, respectively.

The Eco-Hind III fragment containing the multi-restriction sites was cutout from M13 mp10 (Vieira eta al, supra) and ligated to Eco RI-Hind IIIcut plc245 (Remaut et al, supra) to form pLmp10. The 319 bp Alu Ifragment containing the nutR, t_(R1) sites and a part of the cII genewas cut out from pKG1805 (McKenney, K PhD Dissertation, The JohnsHopkins University (1982)) and cloned into the Sma I site of M13 mp10 inthe same orientation with respect to the beta-galactosidase alphapeptidegene. The Eco RI-Hind III fragment containing the lambda DNA sequencewas then cut out and cloned into the Eco RI-Hind III site of pLmp10 toyield pLcII.

A complete human beta-globin cDNA sequence was reconstructed by joiningrestriction fragments prepared from an incomplete cDNA clone (pJW102)(Wilson et al, Nucleic Acids Research 5, 563-581 (1978)) and a genomicDNA clone (Lawson et al, Cell 21, 647-651 (1980)) and cloned into theSma I-Hind III site in M13 mp9. M13 mp9 beta cDNA thus obtained wasopened at the Nco I site which is located at the initiation codon andtreated with Klenow DNA polymerase (Boehringer Mannheim) in the presenceof 100 micro M 4dNTP to obtain flush ends. The beta-globin cDNA sequencewas then cut out with Hind III and inserted into the Bam HI(filled-in)-Hind III site of pLcII so that the beta-globin gene wasfused to the lambda cII gene in phase via a small linker DNA derivedfrom M13 mp10.

In order to construct pLcIIFX beta, M13 mp9 beta cDNA was opened withNco I and 40 micro g of DNA was treated with 200 units of mung beannuclease (P-L Biochemicals) in 30 mM Na-acetate pH 4.6, 50 mM NaCl, 1 mMZnCl₂, 5% glycerol at 0° C. for 10 min to remove the 5' protruding end.The beta-globin cDNA sequence was cut out with Hind III and cloned intothe Stu I-Hind III cut M13 mp11 FX. The DNA sequence was determined bythe dideoxy chain termination method (Sanger et al, PNAS 74, 5463-5467(1977)) to ensure that the first valine codon of the beta-globin genewas preceded by the DNA sequence coding for Ile-Glu-Gly-Arg. Then, theBam HI fragment containing a part of the beta-globin sequence was cutand cloned into Bam HI digested pLcII beta to form pLcIIFX beta, asshown in FIG. 1b.

Construction of pLcII FX beta FX alpha

M13 mp11 FX beta-globin DNA was prepared in single-stranded form and aBglII site was introduced into the beta-globin sequence using amutagenic ol igodeoxynucleotide, dACCAACTTCAGATCTGTTACCTTG, cal ledKN83, to obtain mp11 cII FX beta FX. The replicative form of this mutantclone was digested with SacI and Hind III, and the resulting cII FX betaFX fragment was cloned into Sac I/Hind III cut pLmpII to form pLcII FXbeta FX. This recombinant plasmid was digested with BglII and the 5'terminal phosphate groups of the linear DNA were removed with calfintestinal alkaline phosphatase. The replicative form of mp11 FXalpha-globin was digested with BamH1 and the FX alpha-globin containingfragment was ligated with the linearised pLcII FX beta FX to form pLcIIFX beta FX alpha. This plasmid encodes a fusion protein consisting ofthe 31 amino-terminal residues of the lambda phage cII protein, thetetrapeptide Ile-Glu-Gly-Arg, the 20 amino-terminal residues of humanbetaglobin, the tetrapeptide Ile-Glu-Gly-Arg and human alphaglobin atthe carboxyl end. Transcription of the fusion protein gene is initiatedat the lambda P_(L) promoter and is regulated by lambda repressor.

Expression of Recombinant Conventional Alpha and Beta Globin

A defective lambda phage lysogenic strain of E.coli QY13 (a gift from S.Brenner, and available on request from Medical Research Council)harboring pLcIIFX beta FX alpha-globin or pLcIIFX beta-globin was grownat 30° C. in 2xTY medium (16 g tryptone, 10 g yeast extract and 5 gsodium chloride-liter) in the presence of ampicillin (25 micro g/ml).When the optical density (600 nm) reached 1.5-1.6, the temperature wasquickly raised and maintained at 42° C. for 15 min, followed by furtherincubation at 37° C. for 3-4 hr. The cells were harvested and frozen inliquid nitrogen.

The cells (100 g) were thawed and suspended in 80 ml of 50 mM Tris-HCl(pH 8.0)/25% sucrose (wt/vol)/1 mM EDTA and lysed by addition oflysozyme (200 mg). Then, MgCl₂, MnCl₂ and DNase I were added to finalconcentration of 10 mM, 1 mM and 10 micro g/ml, respectively. After 30min incubation 200 ml of 0.2M NaCl/1% deoxycholic acid/1.6 % NonidetP-40 (vol/vol)/20 mM Tris-HCl(pH7.5)/2 mM EDTA were added to the lysate,which was then centrifuged at 5000 ×g for 10 min. Then the pellet wassuspended in 0.5% Triton X-100/1 mM EDTA and centrifuged. This procedurewas repeated until a tight pellet was obtained. The protein pellet wasfinally dissolved in 8M urea/25 mM Tris-HOAc (pH5.0)/1 mMEDTA/1 mMdithiothreitol in the case of cIIFX beta-globin fusion protein. In thecase of cIIFX beta-FX-alpha-globin fusion protein, the pellet was firstdissolved in 6M guanidine hydrochloride/25 mM Tris-HOAc (pH 5.0)/1 mMEDTA/1 mM dithiothreitol.

The fusion protein solution was then applied to a 4×10 cm CM-Sepharose(Pharmacia) column equilibrated with the same buffer. The fusion proteinwas eluted with a linear gradient formed with 500 ml of 8M urea/25 mMTris-HOAc pH 5.0/1 mM EDTA/1 mm dithiothreitol and 500 ml of the samebuffer with 0.2M NaCl. The fusion protein was further purified on a 5×60cm Sephacryl S-200 column equilibrated with 5M guanidine-HCl/50 mMTris-HCl/ 1 mMEDTA/1 mM dithiothreitol to remove any trace ofimpurities. The combined fraction was extensively dialyzed against 50 mMTris-HCl (pH 8.0)/0.5M urea/1 mM CaCl₂.

Protein Cleavage

The cIIFX beta FX alpha-globin or cIIFX beta-globin fusion protein wasincubated at 0° C. with blood coagulation factor X_(a) that had beenactivated with Russell's viper venom immobilized on cyanogenbromideactivated Sepharose-6B. 100 micro 1 aliquots were removed afterintervals of 2, 5, 15, 30, 60 and 120 minutes. 100 ul of protein samplebuffer (Laemmli, 1970) and 1 ul of 100 mM DTT were added to eachaliquot, which was then boiled before being applied to an SDSpolyacrylamide gel. Factor X_(a) cutting of the cIIFX beta FX alphafusion protein gives rise to a number of polypeptide products. This isdue to the presence of two recognition sites within the protein.Complete digestion releases three polypeptides, a cII protein fragmentand a beta-globin fragment, both with the tetrapeptide Ile-Glu-Gly-Argat the carboxyl terminus, and the desired alpha-globin. Partialdigestion of the fusion protein gives two other products.

Factor Xa cleavage of cIIFX-beta yields two products, a cII fragment andthe desired beta globin.

Formation of Semi-Artificial Hb with alpha-globin produced in E.coli

25 mg of hemin-C1 was dissolved in 2.5 ml of 0.1N KOH and 30 dilutedwith 20 ml of water and 2.5 ml of 1M KCN. The native beta chain wasdiluted in 20 mM K phosphate buffer pH 5.7, 1 mM EDTA, 1 mMdithiothreitol (DTT) and bubbled with CO. Alpha globin produced inE.coli was dissolved in 8M urea/50 mM Tris-C1 pH 8/1 mM EDTA/1 mM DTT atthe concentration of 5 mg/ml and incubated at room temperature for 3hours. The alpha-globin solution was added dropwise to 20 volumes of 30mM K phosphate buffer pH 5.7, 1 mM EDTA, 1 mM DTT with gentle stirring.The hemin-dicyanide solution (1.2 equivalent to the alpha-globin) wasadded dropwise to the alpha-globin solution and the beta chain was addedin slight excess. The semi-artificial Hb was dialyzed overnight against0.1M K phosphate pH 7.6 1 mM EDTA, 1 mM KCN.

Formation of semi-artificial Hb with beta-globin produced in E. coli

Beta-globin (100 mg) was dissolved in 8M urea, 50 mM Tris-C1 pH 8.0, 1mM DTT, 1 mM EDTA at the concentration of 5 mg/ml and incubated at roomtemperature for 1 hr. The beta-globin solution was added dropwise to 16volumes of alpha chain solution (either isolated from Hgb A, or producedby recombinant means) (3.2 mg/ml) in 10mM Tris-Cl pH 8.0. Thehemin-dicyanide solution (1.2 equivalents to beta-globin) was addeddropwise with gentle stirring. The semi-artificial Hb was dialyzedagainst 2 changes of 0.1M K phosphate pH 7.4 1 mM EDTA, 1 mM KCN.

Formation of wholly artificial hemoglobin

The lyophilized recombinant alpha and beta globins were dissolved in 8Murea/50 mM Tris-Cl, pH 8.0/1 mM EDTA/1 mM DTET, diluted to aconcentration of 5 mg/ml and incubated at room temperature for 3-4hours. The alpha globin was then diluted to 0.3 gm/ml with chilled 20 mMK₂ HPO₄, pH 5.7/1 mM EDTA/1 mM DTT. Hemin (25 mg) was dissolved in 2.4mg 0.1M KOH, diluted with an equal volume of 1M KCN; this solution wasthen made 0.1 mg.ml in hemin and 20 mM K₂ HPO₄, pH 6.7 with stockphosphate buffer. Hemin from this solution was added to a 2.8 molarexcess to chilled alpha-globin; and equal molar amount of beta-globinwas added and the solution was dialyzed at 4° C. overnight against 0.1MK₂ HPO₄, pH 7.6/1 mM EDTA/1 mM KCN.

Purification of the semi-artificial or wholly artificial Hb

The artificial Hb was concentrated by ultrafiltration using diaflo PM-10membrane (Amicon) and transferred into a 200 ml screw-top test tube witha rubber septum. The hemoglobin solution was deoxygenated by evacuationand flushing with N₂, and then the solution was saturated with CO. 100mMSodium dithionite solution was prepared anaerobically in a 20 mlscrew-top test tube with rubber septum. 4.5 equivalents of dithionitewere added to the Hb solution with a syringe, and the mixture incubatedon ice for 15 min.

The Hb solution was gel-filtered against 10 mM Na phosphate buffer pH6.0 on a 4×40 cm Sephadex G-25 (fine) column. The Hb was then applied toa 2×10 cm CM-52 (Whatman) column equilibrated with the same buffer andthe chromatography was developed with a linear gradient of 500 ml 10 mMNa phosphate buffer pH 6.0 and 500 ml of 70 mM sodium phosphate bufferpH 6.9. CO was removed from Hb by photolysis under a stream of oxygen.This Hb shows native oxygen binding properties.

A wholly artificial hemoglobin may be prepared by the combination ofalpha-globin and beta-globin both produced in E.coli, or any other hostof a non-erythroid nature, with a source of heme.

Example 2: Production of Low-Affinity Hemoglobin Mutants Constructionand Mutagenesis of pLcIIFX beta-globin(Thr¹⁰²)

A synthetic oligonucleotide of sequence dGGAGCCTGAAAGTCTCAGGA wasdesigned from published mRNA sequence information [Bunn & Forget, eds.,Hemoglobin: Molecular, Genetic and Clinical Aspects, W. B. Saunders Co.,Philadelphia, Pa., 169-222 (1986)] and synthesized on a controlled glasssupport. The oligonucleotide was gel purified [Lloyd et al.,BioTechniques 4, 8-10 (1986)] and used to prime the site-specificmutagenesis of M13 mp10 cIIFX beta -globin by the methods of Zoller andSmith [Methods in Enzymology 100, Academic Press, New York, 468-500(1983)].

The mutagenic oligonucleotide was complementary to the beta-chainstructural gene sequence flanking and centered upon the wild-type codonfor Asn¹⁰². At this triplet specific base substitutions were designedinto the oligonucleotide to specify ACT-Thr¹⁰², the amino acid sequencealteration which is characteristic of the Kansas beta-globin mutant[Bonaventura & Riggs, J. Biol. Chem. 243,980-991 (1968)]. The particularThr codon employed in this substitution, while differing from that foundin the original Kansas isolate (Bonaventura and Riggs, supra), ispreferentially utilized in highly expressed E. coli genes [Grantham etal., Nucleic Acids Res. 9, r43-r74 (1981)].

Production of Mutant beta-Globin

The products of the in vitro mutagenesis reaction were transformed intocompetent E. coli ^(M) Z-1 [galK_(am) 8attL BAmN₇ N₅₃ cI857 Hl, his⁻,ilv⁻, bio⁻ N⁺, a gift of Dr. K McKenney and available on request fromthe Medical Research Council), by standard procedures of CaCl₂ -shock[Maniatis et al., Molecular Cloning, Cold Spring Harbor Laboratory, NewYork, 250-251 (1982); Nagai & Thogersen, Methods in Enzymology, supra].

Transformants harboring the desired mutant M13 bacteriophage constructswere then identified by differential plaque-hybridization screenings athigh stringency using gamma[³² P]-end-labeled oligonucleotides asprobes.

The reactants used to prepare each of the phosphorylated hybridizationprobes were 300 pM (2 ug) of oligonucleotide, 100 pM (0.7 mCi) gamma-[³²P]-ATP (specific activity approximately 6000 Ci/mM), and 15 units T4polynucleotide kinase in a total reaction mixture of 50 ul. After 37° C.incubation for 2 h, the end-labeled oligomers were purified away fromorthophosphate and unincorporated precursor nucleotide using reversephase C-18 sep-paks (Waters Associates Milford, Mass.). This latterprocedure involved loading the phosphorylation reaction mixture onto theC-18 cartridge in an aqueous salt solution, eluting orthophosphate andunincorporated ATP with water followed by 10% methanol, and then elutingthe purified oligomer with 60% methanol. The probes employedcomparatively in the differential hybridization analyses were both themutagenic oligonucleotide and another 20-mer (dGGAGCCTGAAGTTCTCAGGA)which is perfectly complementary to the wild-type beta-chain DNAsequence in the same coding region.

After identification and plaque purification (Zoller & Smith, supra) ofseveral of the desired M13 phage constructs, one of the resultant Thr¹⁰²mutants, termed M13 mp10 cIIFX beta-globin (Thr¹⁰²), was furtherverified by DNA sequence analysis [Sanger et al., Proc. Natl. Acad. Sci.USA 74, 5463-5467 (1977)] to contain the desired mutation at codon-102,and only that particular amino acid sequence alteration in thebeta-chain structural gene coding sequence.

A large scale preparation of M13 mp10 cIIFX -betaglobin(Thr¹⁰²) RF DNAwas conducted as follows [Recinos, Ph.D. Dissertation, VanderbiltUniversity (1987)]. The host E. coli was grown at 37° C. overnight in M9minimal medium (Maniatis et al., supra) plus 2 ug/ml thiamine. 0.3 ml ofthis cell culture was then diluted (1:50) into 14.7 ml 2X YT medium andgrowth at 37° C. was continued for an additional 2 h. The latter culturewas again diluted (1:10) into a final volume of 150 ml 2X YT, and thiscell solution was inoculated with the plaque purified mutant M13 phageconstruct at a multiplicity of infection of approximately one. Thisphage infection was then shaken vigorously at 37° C. for 14 h, and cellsfor RF preparation were harvested by centrifugation (5000 ×g, 10 min, 4°C.). The mutant phage supernatant was stored at -20° C. for use inscaled-up versions of the protocols (Zoller & Smith, supra) for phagepurification and for single-stranded template preparation.

Double-stranded RF DNA was purified from the cell pellets as follows.Pellets were frozen in an alcohol dry-ice bath for 10 min, thawed at 20°C. and completely resuspended on ice in 10 ml 25% sucrose, 50 mMTris-HCl (pH 8.0). Lysozyme was added to a final concentration of 4mg/ml, and incubation was continued on ice for 5 min. EDTA was thenadded to a final concentration of 80 mM, and again after 5 min on ice,an equal volume of 0.5% Triton X-100, 50 mM Tris-HC1 (pH 8.0), 62.5 mMEDTA was added. This solution was kept on ice for 15 min more, and then5M NaCl was added to a final concentration of 1M. The last solution wasloaded into Beckman Type 70 Ti rotor bottles, and after a furtherincubation on ice for 3 h, was centrifuged at 40,000 rpm for 75 min at15° C. RF DNA was decanted with the supernatant and precipitated at -20°C. for 20 min with the addition of an equal volume of isopropanol. DNAprecipitates were pelleted and resuspended in 10 mM Tris-HCl (pH 8.0), 1mM EDTA, 100mM NaCl, and treated with RNase (final conc. 100 ug/ml) for2 h at 37° C. This solution was phenol and chloroform extracted (onetime each), and the DNA was ethanol precipitated and resuspended in 30ml 10mM Tris-HCl (pH 8.0), 1 mM EDTA. The DNAs were twice banded byCsCl-ethidium bromide density gradient equilibrium centrifugation. FormI DNA bands were extracted 4× with CsCl-saturated isopropanol to removeethidium bromide, and DNA and CsCl were ethanol precipitated. CsCl wasremoved from DNA pellets by resuspension in and dialysis against 10 mMTris-HCl (pH 8.0), 0.2 mM EDTA. A final ethanol precipitation andresuspension in 0.5 ml Tris-HCl (pH 8.0) yielded 150 ug of purified M13mp10 cIIFX beta-globin(Thr¹⁰²) RF DNA for use in subcloning the mutantbeta-globin structural gene into the beta-globin expression construct.

The mutated beta-chain sequence was moved into the beta-chain expressionvector, pLcIIFX beta-globin (nic⁻), by the following procedures. Mutantclone RF (50 ug) was restriction enzyme digested with SaC I and HindIII, and the resultant cIIFX beta-globin (Thr-102) fragment was isolatedfrom a 1% preparative agarose gel (Maniatis et al., supra) andgel-purified by a phenol freeze-thaw procedure [Benson, BioTechniques 2,77-78 (1984)]. Approximately 200 ug of expression vector DNA wasisolated and purified from E. coli QY13 transformant cell pellets bymethods nearly identical to those described above for the Rfpreparation. This plasmid DNA (20 ug) was similarly restricted with SaCI and Hind III and further treated with bacterial alkaline phosphatase(Bethesda Research Laboratories, Gaithersburg, Md., as directed) toremove the 5' phosphates from the vector DNA, thereby preventingrecircularization without insert DNA in subsequent ligation reactions.

The purified mutant insert DNA fragment was then ligated back into theexpression construct at moderate insert end-concentration, replacing thewild-type protein coding sequences previously therein. Ligation reactionconditions (modified from procedure of New England Biolabs, Inc.,Beverly, Mass.) were: 11 ug vector DNA and 2.1 ug purified insert DNA in500 mM Tris-HCl (pH 7.8), 100 mM MgCl2 6 mM ATP, 2 mM dithiothreitol;total reaction volume =125 ul. Incubation for the ligation was at 16° C.for 10 h. The final ligation reaction mixture was used to transformcompetent E. coli QY13 with selection for ampicillin resistance.Transformants harboring the desired plasmid construct for the expressionof mutant beta-chain were identified by differential colonyhybridization screenings [Grunstein & Hogness, Proc. Natl. Acad. Sci.USA 72, 3961-3965 (1975), with modifications] using the end-labeledmutagenic and wild-type oligonucleotides described above as probes. Thecorrect plasmid construct was further verified by restriction analysisand by its expression of a protein which is chromatographeddifferentially from the wild-type cIIFX beta-globin fusion product byHPLC. The mutant beta-globin was produced, purified and combined withalpha-globin as described for native beta-globin.

Construction and Mutagenesis of pLcIIFX beta-globin(Ile⁶⁷)

Mutation of the val⁶⁷ codon was introduced into the beta-globin cDNAsequence in M13 mp10 cIIFX beta-globin using the mutagenic primer(dGCACCGAGGATTTTCTTGCC) as above. The mutant beta-globin was produced,purified and combined with alpha globin as described for nativebeta-globin to obtain a mutant hemoglobin.

Construction add Mutagenesis of pLcIIFX beta-globin (phe⁶⁷)

Mutation of the his⁶³ codon was introduced into the beta-globin cDNAsequence in M13 mp10 cIIFX beta-globin using the mutagenic primer(dTTCTTGCCGAAAGCCTTCA) as above. The mutant beta-globin was produced,purified and combined with alpha globin as described for nativebeta-globin to obtain a mutant hemoglobin.

Characterization of Mutant Hemoglobin

Oxygen equilibrium studies for Hgb (beta phe⁶³) Hgb (beta ile⁶⁷) wereperformed in 0.05M bis-Tris pH 7.4, 0.1M NaCl, at 25° C. using theautomated recording apparatus of K. Imai (Meth. Enz. 76, 438-449, 1981)and for Hgb (beta thr¹⁰²) in 0.1M HEPES pH 7.4, 0.1M NaCl using a thinlayer optical cell (Gill, S. J. Meth. Enz. 76, 427-438, 1981). Resultsare shown in Table 3.

Example 3: Blood Substitute Solution

The purified hemoglobin is incorporated into a physiologicallyacceptable blood substitute solution. A preferred solution includes thefollowing components:

    ______________________________________                                        Hgb (gm/l)        60-120                                                      Sodium (mEq/l)   135-145                                                      Potassium (mEq/l)                                                                              3.5-4.5                                                      Chloride (mEq/l)  90-110                                                      ______________________________________                                    

Preferably, the solution has a pH of 7.3-7.5, an osmolality of 280-310,and an oncotic pressure of 20-30 mm Hg. Osmolality is controlled byconcentration of hemoglobin and of the electrolytes, as well as by theoptional ingredient glucose (preferably 0-30 gm/l). The oncotic pressureis controlled by the concentration of the hemoglobin and by its degreeof crosslinking. Agents, such as albumin (0-70 gm/l), dextran (0-100gm/l) and polyethylene glycol (0-25 gm/l) may be added to increaseoncotic pressure. Moreover, to reduce the degree of methemoglobinformation, anti-oxidant or free radical scavengers, such as mannitol(0-20 gm/l), glutathione (0-4 gm/l), ascorbic acid (0-0.3 gm/l) andvitamin E (0-100 IU/1) may be provided.

If a low oxygen affinity mutant hemoglobin is employed, it may bedesirable or necessary to adjust the P₅₀ of the solution to thepreferred level by suitable choice of electrolytes, pH and othercharacteristics of the composition. Preferably, the final solution has aP₅₀ of 24-32 torr under standard physiological conditions.

Example 4: Preparation of Cys Substitution Mutants of Alpha and BetaGlobin

Standard techniques of molecular biology according to Maniatis et al.(5) were used throughout.

Subcloning of haemoglobin genes

Hoffman, et al., Ser. No. 07/349,623, filed May 10, 1989, incorporatedby reference, describes the cloning of alpha and beta globin genes intothe commercially available plasmid pKK 223 (Pharmacia/LKB, Piscataway,N. J.). The resulting expression vector served as a convenient source ofthe genes and was cleaved with HindIII and SmaI to excise the 1016 basepair fragment carrying the genes. However, the alpha and beta globingenes could have been obtained from any convenient source. The geneswere isolated from the vector DNA using Geneclean (Bio 101, Inc.) andligated into the high copy plasmid pUC9 which had been linearized at itsmultiple cloning site. The newly constructed vector (pCHB) was thentransformed into DH5α competent cells (BRL). Positive transformants wereidentified by restriction analysis. The plasmid resulting was used asthe basis of all subsequent mutagenic constructs.

Mutagenesis of the hemoglobin genes

The same basic technique was used for the modification of each codon. Toavoid repetition only the mutagenesis of codon 97 beta will be describedin detail here.

To mutate each codon, two oligonucleotides were required that werecomplementary to each other, and were identical to the wild-typesequence except save for the missense mutations necessary to alter thecodon specified. A list of the oligonucleotides used is given in Table5. Each oligonucleotide was designed to create a double-strandedsequence after annealing to its complementary sequence, of 51-55 basepairs in length. In addition, each double-stranded oligonucleotidecreated the appropriate "sticky end" at its 5' and 3' extremities tofacilitate its ligation into the relevant gene for successfulmutagenesis. For example, to modify the codon 94 it was necessary forthe double stranded sequence to exhibit the "sticky end" of an MluIdigestion at its 5' end and a HpaI "blunt end" at its 3' end. Since theother three codons mutagenized were localized within a small region ofthe beta gene, each mutagenic double stranded oligonucleotide displayeda CacI "sticky end" at its 5' end and a SpeI "sticky end" at its 3' end.All oligonucleotides used in this work (and in the subsequent sequencingstep) were synthesized on an Applied Biosystems oligonucleotidesynthesizer.

With such large oligonucleotides, it was important to purify them priorto use. Consequently, the 97 beta sense (55met) and 97 beta antisense(63mer) oligonucleotide were separated from the prematurely terminatedoligonucleotide fragments on an 8M urea/12% polyacrylamide gel. Theappropriate bands were then excised, purified, and quantified at 260 nm.

The sense and antisense oligonucleotides were then phosphorylated withT4 polynucleotide kinase before equimolar amounts of each were annealedtogether. pCHB DNA was double-digested with SacI and SpeI and isolatedusing Geneclean. Finally, the mutagenic double-stranded oligonucleotidewas ligated into the linearized pCHB vector, and then transformed intoDH5α competent cells.

Restriction analysis was used initially to identify putativetransformants which were then more extensively analyzed via plasmidsequencing. The Sequenase kit (United States Biochemicals) was used tocarry out the DNA sequencing. Sequencing of the whole of the 1 kb globingene sequences required the design and synthesis of a number ofoligonucleotide primers (Table 6). These were used in addition to theUniversal primer and the reverse Universal primer (Table 6) whichallowed the extremes of the insert to be sequenced. Having identified apositive mutant the clone was named pCHB0097. With the construction ofthe mutant pCHB4400 (containing the mutagenized codon 44α), it onlyremained to subclone the 512bp PstI - HindIII fragment of pCHB0097 (withthe abberrant gene) into the identically digested vector pCHB4400 beforethe final construct, containing both mutagenized alpha and beta genes,was created. This clone was designated pCHB4497. The success of thisstep was confirmed by both restriction and sequence analysis. The sameprotocol was then repeated for all the other mutants subsequentlyconstructed.

References for Example 4

1. Perutz, M. F. (1979). Ann. Rev. Biochem. 48, 327-386.

2. Nagai, K., Perutz, M. F., Poyart, C. (1985). Proc. Natl. Acad. Sci.(USA). 82, 7252-7255.

3. Fermi, G., Perutz, M. F., Shaanan, B., Fourme, .R (1984). J. Mol.Biol. 175, 159-174.

4. Shaanan, B. (1983). J. Mol. Biol. 171, 327-386.

5. Maniatis, T., Fritsch, E. F., Sambrook, J. (1982). In MolecularCloning: A Laboratory Manual (Cold Spring Harbor Lab., Cold SpringHarbor, N.Y.).

Example 5: Production of Recombinant Hemoglobin and Conversion toDisulfide Cross-Linked Hemoglobin

Hoffman, et al., Ser. No. 07/349,623, now abandoned, incorporated byreference herein, describes the coexpression of alpha and beta globinsand the in vivo assembly of hemoglobin from the expression products. Ourmethod was identical to that described by Hoffman, et al., Ser. No.07/349,623 except for the use of differently mutated alpha and betaglobin genes. In brief, we constructed an artificial polycistronicoperon comprising a Tac promoter, a short cistron described in Schoner,et al., Meth. Enzymol., 153:401-16 (1987), the mutant alpha globin gene,an intercistronic region, the "Schoner cistron" again, and the mutantbeta globin gene.

To express recombinant Hgb that could form intersubunit disulfide bonds,the gene sequence containing alpha⁴⁴ -cys/beta⁹⁷ -cys needed to becloned back into the pKK-223 expression plasmid. pCHB4497 wasrestriction digested with Smal and Hindlll and the approximately 1 kbfragment containing the alpha/beta globin genes isolated byelectrophoresis and Geneclean. This fragment was then cloned into Smaland Hindlll cut pKK-223 with T4 ligase. E. coli were transformed withthis ligation mixture and individual clones were isolated. Plasmidcontaining the alpha⁴⁴ -cys/beta⁹⁷ -cys genes in the pKK-223 expressionsystem was identified as pHB-cysα44β97.

E. coli were transformed with the plasmid pHB-cysα44β97. Two liters ofTB medium containing ampicillin (100 μg/ml) was inoculated with 20 mL ofan overnight culture of the E. coli clone, and grown to an opticaldensity at 600 nm (OD₆₀₀) of 2.1 at 37° C. The culture was induced withIPTG (2.5 mM final concentration) and grown to an OD₆₀₀ of 3.5.

The cells (40 gm) were collected by centrifugation at 10,000 xg andsuspended in 80 mL of lysis buffer (50 mM Tris-HCl, pH 8.0, 25% sucrose,1 mM EDTA). Ten milliliters of lysozyme solution (18 mg/ml in lysisbuffer) was added and the mixture incubated on ice for 30 min. MgCl₂,MnCl₂, and DNAse I (Sigma, St. Louis, Mo.) were added to finalconcentrations of 10 mM, 1 mM and 10 μg/mL, respectively. The cells wereincubated at room temperature for 1 hour and an equal volume of asolution containing 1% one percent deoxycholic acid, 1% Nonidet P-40, 20mM Tris-HCl pH 7.5, 2 mM EDTA was added to the lysate.

Particulate material was removed by centrifugation at 10,000 ×g for 10min. The pH of the supernatant was adjusted to 6.0 and the supernant wasloaded onto a CM-cellulose column (2.5×15 cm) equilibrated in 10 mMNAPO₄, pH 6.0 at 4° C. The column was washed with two bed volumes of 10mM NaPO₄, pH 6.0 followed by a linear gradient of 10 mM NAPO₄, pH 6.9 to20 mM NaPO₄, pH 9.0 (400 mL total volume). Fractions containing a red(oxyhemoglobin) solution were combined; an aliquot of this solution wasscanned from 650 nm to 400 nm revealing a spectrum identical to that foroxyhemoglobin. An aliquot of the same peak was analyzed by SDS-PAGEelectrophoresis with hemoglobin as molecular weight standard and wasfound to contain two protein bands migrating with native alpha and betaglobin. The purified recombinant Hgb (alpha⁴⁴ -cys/beta⁹⁷⁻ cys) wasfound to have an optical spectrum identical to that of oxy-hemoglobin.The mutant Hgb was tested for titratable cysteine residues usingp-hydroxymercuribenzoate according to the procedure of Boyer, P. (J.Amer. Chem. Soc. 1954, 76, 4331) and found to have 6.2 moles titratablecysteines/mole Hgb; Hgb A_(o) contained 2.2 moles titratablecysteines/mole Hgb under identical conditions. This result confirms thatHgb is being produced with additional cysteine residues. The Hgbsolution was deoxygenated by flushing with dry N₂ gas to approximately 1torr pO₂, tightly stoppered and stored at 4° C. The solution wasperiodically sampled under deoxy conditions and assayed for titrablecysteine residues. After 72 hours the cysteine-containing Hgb solutioncontained only 2.5 moles titratable cysteines/mole Hgb, nearly identicalto that of a solution of Hgb A_(o) (2.2 moles titratable cysteines/moleHgb). The loss of active cysteines indicates that upon standing in thedeoxy, or T state, the molecule has formed disulfide bonds.

                                      TABLE 1                                     __________________________________________________________________________    NATURAL LOW AFFINITY HEMOGLOBIN MUTANTS                                       __________________________________________________________________________                       P.sub.50 *                                                 Hemoglobin                                                                            Alpha Mutant                                                                             RBC-Free Hgb                                                                          Whole Blood (nl)                                                                       Area of Mutant                                                                        Reference                         __________________________________________________________________________    Hirosaki                                                                               43(CD1) phe-->leu                                                                       n/a              heme    1, 2                              Torino   43(CD1) phe-->val                                                                       n/a              heme    1, 3                              Moabit   86(F7) leu-->arg  30.6 (26.4-29.2)                                                                       heme     4                                Titusville                                                                             94(G1) asp-->asn                                                                        15.8(4.7)        α.sub.1 β.sub.2                                                             5                                __________________________________________________________________________                       P.sub.50 (mmHg)                                            Hemoglobin                                                                            Beta Mutant                                                                              Hbg (nl)                                                                              Whole Blood (nl)                                                                       Area of Mutant                                                                        Reference                         __________________________________________________________________________    Raleigh  1 val-->acetyl ala                                                                       4.0(2.2)        DPG site                                                                               6                                Connecticut                                                                            21(83) asp-->gly                                                                         5.0(2.2)        B-E hetices                                                                            7                                Moscva   24(86) gly-->asp                                                                        14.8(12.6)       B-E helices                                                                            8                                Rothschild                                                                             37(C3) trp-->arg                                                                         3.5(2.0)        α.sub.1 β.sub.2                                                             9                                Hazebrouck                                                                             38(C4) thr-->pro  36 (27-29)                                                                             α.sub.1 β.sub.2                                                            10                                Hammersmith                                                                            42(CD1) phe-->ser                                                                       n/a              heme/α.sub.1 β.sub.2                                                       1, 11                             Louisville                                                                             42(CD1) phe-->leu                                                                       24(21)           heme/α.sub.1 β.sub.2                                                       12, 13                            Sendagi  42(CD1) phe-->val                                                                       3.75(3.05)       heme/α.sub.1 β.sub.2                                                       14                                CheverLey                                                                              45(CD4) phe-->ser 38.7 (28.7)                                                                            heme    15                                Okatoosa                                                                               48(CD7) leu-->arg                                                                       0.95(0.7)                                                                             30(26)   C-D helices                                                                           16                                Bologna  61(E5) lys-->met  37.6 (27.0)                                                                            B-E helices                                                                           17                                Cairo    65(E9) lys-->gtn  41(31)   heme    18                                Chico    66(E10) lys-->thr                                                                       10.1(5.0)                                                                             38.0 (27.2)                                                                            heme    19                                Bristol  67(E11) val-->asp 25.0 (19.0)                                                                            heme    20                                Seattle  70(E14) ala-->asp 43.5 (28.1)                                                                            heme    21, 22                            Vancouver                                                                              73(E17) asp-->tyr                                                                       n/a                      1, 23                             Korle-Bu                                                                               73(E17) asp-->asn                                                                       n/a                      1, 24                             Mobite   73(E17) asp-->val                                                                       n/a                                                        Rahere   82(EF6) lys-->thr                                                                       15.5(11.0)       DPG site                                                                              26                                Pyrgos   83(EF7) gly-->asp          External                                                                              27                                Roseau-Pointe                                                                          90(F6) glu-->gly  38(28)   α.sub.1 β.sub.2                                                            28                                Agenogi  90(F6) glu-->lys                                                                        9.0(6.8)         α.sub.1 β.sub.2                                                            29                                Caribbean                                                                              91(F7) leu-->arg                                                                        28.0(21.0)       heme    30                                Kansas  102(G4) asn-->thr                                                                        28.0(9.0)        α.sub.1 β.sub.2                                                            31                                Beth lsraet                                                                           102(G4) asn-->ser  88.0 (26.0)                                                                            α.sub.1 β.sub.2                                                            32                                Saint Maride                                                                          102(G4) asn-->tyr  52 (28)  α.sub.1 β.sub.2                                                            33                                Richmond                                                                              102(G4) asn-->lys                                                                        n/a              α.sub.1 β.sub.2                                                            1, 34                             Burke   107(G9) gly-->arg                                                                        9.3(7.7)         heme    35                                Yoshizuka                                                                             108(G10) asn-->asp                                                                       12.9(9.0)        α.sub.1 β.sub.1                                                            36                                Presbyterian                                                                          108(G10) asn-->lys                                                                       6.3(2.5)         α.sub.1 β.sub.1                                                            37                                Peterborough                                                                          111(G13) val-->phe                                                                       14.0(9.0)        α.sub.1 β.sub.1                                                            38                                New York                                                                              113(G15) val-->glu                                                                       n/a              G-helix 1, 39                             Hope    136(H14) gly-->asp                                                                       n/a              heme    1, 40                             Himeii  140(H18) ala-->asp                                                                       5.8(4.5)                                                   __________________________________________________________________________     Parenthetical values are that investigator's measured P.sub.50 for            conventional Hgb A in RSCfree or RSCbound state, as indicated                 References for Table 1                                                        1) Hemoglobin 1987, 11, 241-308.                                              2) Ohba, Y.; Miyaji, T.; Matsuoka, M.; Yokoyama, M. Numakura, H.; Nagata,     K.; Takebe, Y.; Izumu, Y.; Shibata, S. Biochemi. Biophys, Acta 1975, 405,     155-160.                                                                      3) Beretta, A.; Prato, V.; Gallo, E.; Lehmann, H. Nature 1968, 217,           1016-1018.                                                                    4) Knuth, A.; Pribilla, W.; Marti, H. R.; Winterhalter, K. H. Acta            Haematol 1979, 61, 121-124.                                                   5) Schneider, R. G.; Atkins, R. J.; Hosty, T. S.; Tomlin, G.; Casey, R.;      Lehmann, H.; Lorkin, P. A.; Nagei, K. Biochem Biophys, Acta 1975, 400,        365-373.                                                                      6) MooPenn, W. F.; Bechtel, K. C.; Schmidt, R. M.; Johnson, M. H.; Jue, D     L.; Schmidt, D. E.; Dunlap, W. M.; Opella, S. J.; Boneventura, J.;            Boneventura, C. Biochemistry 1977, 16, 4872-4879.                             7) MooPenn, W. F.; McPhedran, P.; Bobrow, S.; Johnson, M. H.; Jue, D. L.;     Olsen, K. W. Amer. J. Hematol 1981, 11, 137-145.                              8) Idelson, L. I.; Didkowsky, N. A.; Casey, R.; Lorkin, P. A.; Lehmann, H     Nature 1974, 249, 768-770.                                                    9) Gacon, G.; Belkhodja, O.; Wajcman, H.; Labie, D. Febs Lett 1977, 82,       243-246.                                                                      10) Blouquit.; Delanoe, Garin, J.; Lacombe, C.; Arous, N.; Cayre, Y.;         Peduzzi, J.; Braconnier, F.; Galacteros, F.; Febs Lett. 1984, 172, 155-       158.                                                                          11) Dacie, J. V.; Shinton, N. K.; Gaffney, P. J.; Carrell, R. W.; Lehmann     H. Nature 1967, 216, 663-665.                                                 12) Keeling, M. M.; Ogden, L. L.; Wrightstone, R. N.; Wilson, J. B.;          Reynolds, C. A.; Kitchens, J. L.; Huisman, T. H. J. Clin. Invest. 1971,       50, 2395-2402.                                                                13) Bratu, V.; Larkin, P. A.; Lehmann, H.; Predescu, C. Biochem. Biophys.     Acta. 1971, 251, 1-6.                                                         14) Ogata, K.; Ho, T.; Okazaki, T.: Dan, K.; Nomura, T.; Nozawa, Y.;          Kajita, A. Hemoglobin 1986, 10, 469-481.                                      15) Yeager, A. M.; Zinkham, W. H.; Jue, D. L.; Winslow, R. M.; Johnson, M     H.; McGuffey, J. E.; MooPenn, W. F. Ped. Res. 1983, 17, 503-507.              16) Charache, S.; Brimhall, B.; Milner, P.; Cobb, L. J. Clin. Invest.         1973, 52, 2858-2864.                                                          17) Marinucci, M.; Giuliani, A.; Maffi, D.; Massa, A.; Giampolo, A.;          Mavilio, F.; Zannotti, M.; Tantori, L. Biochem. Biophys. Acta. 1981, 668.     209-215.                                                                      18) Garel, M. C.; Hasson, W.; Coquelet, M. T.; Goosens, M.; Rosa, J.;         Arous, N. Biochem. Biophys. Acta. 1976, 420, 97-104.                          19) Shih, D. T.; Jones, R. T.; Shih, M. F. C.; Jones, M. B.; Koler, R. D.     Hemoglobin 1987, 11, 453-464.                                                 20) Steadman, J. H.; Yates, A.; Huehns, E. R.; Brit., J. Haematol 1970,       18, 435-446.                                                                  21) Stamotoyannopoulos, G.; Parer, J. T.; Finch, C. New Eng. J. Med. 1969     281, 915-919.                                                                 22) Anderson, N. L.; Perutz, M. F.; Stamatoyannopoulos, G. Nature New         Biol., 1973, 243, 275-276.                                                    23) Jones, R. T.; Brimhall, B.; Pootrakul, S.; Gray, G. J. Mol. Evol.         1976, 9, 37-44.                                                               24) KonoteyAhulu, F. I. D.; Gallo, E.; Lehmann, H.; Ringelhann, B. J. Med     Genet. 1968, 5, 107-111.                                                      25) Schneider, R. G.; Hosty, T. S.; Tomlin, G.; Atkins, R.; Brimhall, B.;     Jones, R. T. Biochem Genet. 1975, 13, 411-415.                                26) Sugihara, J.; Imamura, T.; Nagafuchi, S.; Boneventura, J.;                Boneventura, C.; Cashon, R. J. Clin. Invest. 1985, 76, 1169-1173.             27) Tatsis, B.; Sofroniadou, K.; Stergiopoulas, C. I. Blood 1976, 47,         827-832.                                                                      28) Merault, G.; Keclard, L.; SaintMartin, C.; Jasmin, K.; Campier, A.;       Delanoe Garin, J.; Arous, N.; Fortune, R.; Theodore, M.; Seytor, S.; Rosa     J.; Blouquit, Y.; Galacteros, F. Febs Lett. 1985, 184, 10-13.                 29) Imar, K.; Morimoto, H.; Kotani, M.; Shibata, S.; Miyaji, T.1              Matsutomo, K. Biochem. Biophys. Acta. 1970, 200, 197-202.                     30) Ahern, E.; Ahern, V.; Hilton, T.; Serjeant, G. D.; Serjeant, B. E.;       Seakins, M.; Lang, A.; Middleton, A.; Lehmann, H. Febs Lett. 1976, 69,        99-102.                                                                       31) Boneventura, J.; Riggs, A.; J. Biol. Chem. 1968, 243, 980-991.            32) Nagel, R. L.; Lynfield, J.; Johnson, J.; Landeau, L.; Bookchin, R. M.     Harris, M. B. N. Eng. J. Med. 1976, 295, 125-130.                             33) Arous, N.; Braconnier, F.; Thillet, J.; Blouquit, Y.; Galacteros, F.;     Chevrier, M.; Bordahandy, C.; Rosa, J. Febs Lett. 1981, 126, 114-116.         34) Efremov, G. D.; Huisman, T. H. J.; Smith, L. L.; Wilson, J. B.;           Kitchens, J. L.; Wrightston, R. N.; Adams, H. R. J. Biol. Chem. 1969, 244     6105-6116.                                                                    35) Turner, J. W.; Jones, R. T.; Brimhall, B.; DuVal, M. C.; Koler, R. D.     Biochem. Genet. 1976, 14, 577-585.                                            36) Imamura, T.; Fujita, S.; Ohta, Y.; Hanada, M.; Yanase, T. J. Clin.        Invest., 1969, 48, 2341-2348.                                                  37) MooPenn, W. F.; Wolff, J. A.; Simon, G.; Vacek, M.; Jue, D. L.;          Johnson, M. H. Febs Lett. 1978, 92, 53-56.                                    38) King, M. A. R.; Willshire, B. G.; Lehmann, H.; Morimoto, H. Br. J.        Haem. 1972, 22, 125-134.                                                      39) Ranney, H. M.; Jacobs, A. S. , Nagel, R. L. Nature 1967, 213, 876-878     40) Minnich, V.; Hill, R. J.; Khuri, P. D.; Anderson M. E. Blood 1965, 25     830-838.                                                                      41) Ohba, Y.; Miyaji, T.; Murakami, M.; Kadowaki, S. Fujita, T.; Oimoni,      M.; Hatanaka, H.; Ishikawa, K.; Baba, S. Hitaka, K, Imai, K. Hemoglobin       1986, 10, 109-126.                                                       

References for Table 1

1) Hemoglobin 1987, 11, 241-308.

2) Ohba, Y.; Miyaji, T.; Matsuoka, M.; Yokoyama, M.; Numakura, H.;Nagata, K.; Takebe, Y.; Izumu, Y.; Shibata, S. Biochem., Biophys. Acta1975, 405, 155-160.

3) Beretta, A.; Prato, V.; Gallo, E.; Lehmann, H. Nature 1968, 217,1016-1018.

4) Knuth, A.; pribilla, W.; Marti, H. R.; Winterhalter, K. H. ActaHaematol 1979, 61, 121-124.

5) Schneider, R. G.; Atkins, R. J.; Hosty, T. S.; Tomlin, G.; Casey, R.;Lehmann, H.; Lorkin, P. A.; Nagei, K. Biochem Biophys, Acta 1975, 400,365-373.

6) Moo-Penn, W. F.; Bechtel, K. C.; Schmidt, R. M.; Johnson, M. H.; Jue,D. L.; Schmidt, D. E.; Dunlap, W. M.; Opella, S. J.; Boneventura, J.;Boneventura, C. Biochemistry 1977, 16, 4872-4879.

7) Moo-Penn, W. F.; McPhedran, P.; Bobrow, S.; Johnson, M. H.; Jue, D.L.; Olsen, K. W. Amer. J. Hematol 1981, 11, 137-145.

8) Idelson, L. I.; Didkowsky, N. A.; Casey, R.; Lorkin, P. A.; Lehmann,H. Nature, 1974, 249, 768-770.

9) Gacon, G.; Belkhodja, O.; Wajcman, H.; Labie, D. Febs Lett 1977, 82,243-246.

10) Blouquit.; Delanoe, Garin, J.; Lacombe, C.; Arous, N.; Cayre, Y.;Peduzzi, J.; Braconnier, F.; Galacteros, F.; Febs Lett. 1984, 172,155-158.

11) Dacie, J. V.; Shinton, N. K.; Gaffney, P. J.; Carrell, R. W.;Lehmann, H. Nature 1967, 216, 663-665.

12) Keeling, M. M.; Ogden, L. L.; Wrightstone, R. N.; Wilson, J. B.;Reynolds, C. A.; Kitchens, J. L.; Huisman, T. H. J. Clin. Invest. 1971,50, 2395-2402.

13) Bratu, V.; Larkin, P. A.; Lehmann, H.; predescu, C. Biochem.Biophys. Acta. 1971, 251, 1-6.

14) Ogata, K.; Ho, T.; Okazaki, T.: Dan, K.; Nomura, T.; Nozawa, Y.;Kajita, A. Hemoglobin 1986, 10, 469-481.

15) Yeager, A. M.; Zinkham, W. H.; Jue, D. L.; Winslow, R. M.; Johnson,M. H.; McGuffey, J. E.; Moo-Penn, W. F. Ped. Res. 1983, 17, 503-507.

16) Charache, S.; Brimhall, B.; Milner, P.; Cobb, L. J. Clin. Invest.1973, 52, 2858-2864.

17) Marinucci, M.; Giuliani, A.; Maffi, D.; Massa, A.; Giampolo, A.;Mavilio, F.; Zannotti, M.; Tantori, L. Biochem. Biophys. Acta. 1981,668, 209-215.

18) Garel, M. C.; Hasson, W.; Coquelet, M. T.; Goosens, M.; Rosa, J.;Arous, N. Biochem. Biophys. Acta. 1976, 420, 97-104.

19) Shih, D. T.; Jones, R. T.; Shih, M. F. C.; Jones, M. B.; Koler, R.D.; Hemoglobin 1987, 11, 453-464.

20) Steadman, J. H.; Yates, A.; Huehns, E. R.; Brit., J. Haematol 1970,18, 435-446.

21) Stamotoyannopoulos, G.; Parer, J. T.; Finch, C. New Eng. J. Med,1969, 281, 915-919.

22) Anderson, N. L.; Perutz, M. F.; Stamatoyannopoulos, G. Nature NewBiol. 1973, 243, 275-276.

23) Jones, R. T.; Brimhall, B.; pootrakul, S.; Gray, G. J. Mol. Evol.1976, 9, 37-44.

24) Konotey-Ahulu, F. I. D.; Gallo, E.; Lehmann, H.; Ringelhann, B. J.Med. Genet. 1968, 5, 107-111.

25) Schneider, R. G.; Hosty, T. S.; Tomlin, G.; Atkins, R.; Brimhall,B.; Jones, R. T. Biochem Genet. 1975, 13, 411-415.

26) Sugihara, J.; Imamura, T.; Nagafuchi, S.; Boneventura, J.;Boneventura, C.; Cashon, R. J. Clin. Invest. 1985, 76, 1169-1173.

27) Tatsis, B.; Sofroniadou, K.; Stergiopoulas, C. I. Blood 1976,47,827-832.

28) Merault, G.; Keclard, L.; Saint-Martin, C.; Jasmin, K.; Campier, A.;Delanoe Garin, J.; Arous, N.; Fortune, R.; Theodore, M.; Seytor, S.;Rosa, J.; Blouquit, Y.; Galacteros, F. Febs Lett, 1985, 184, 10-13.

29) Imar, K.; Morimoto, H.; Kotani, M.; Shibata, S.; Miyaji, T. I.Matsutomo, K. Biochem Biophys. Acta. 1970, 200, 197-202.

30) Ahern, E.; Ahern, V.; Hilton, T.; Serjeant, G. D.; Serjeant, B. E.;Seakins, M.; Lang, A.; Middleton, A.; Lehmann, H. Febs Lett. 1976, 69,99-102.

31) Boneventura, J.; Riggs, A.; J. Biol. Chem. 1968, 243, 980-991.

32) Nagel, R. L.; Lynfield, J.; Johnson, J.; Landeau, L.; Bookchin, R.M.; Harris, M. B. N. Eng. J. Med. 1976, 295, 125-130.

33) Arous, N.; Braconnier, F.; Thillet, J.; Blouquit, Y.; Galacteros,F.; Chevrier, M.; Bordahandy, C.; Rosa, J. Febs Lett. 1981, 126,114-116.

34) Efremov, G. D.; Huisman, T. H. J.; Smith, L. L.; Wilson, J. B.;Kitchens, J. L.; Wrightston, R. N.; Adams, H. R.; J. Biol. Chem. 1969,244., 6105-6116.

35) Turner, J. W.; Jones, R. T.; Brimhall, B.; DuVal, M. C.; Koler, R.D. Biochem. Genet. 1976, 14, 577-585.

36) Imamura, T.; Fujita, S.; Ohta, Y.; Hanada, M.; Yanase, T. J. Clin.Invest. 1969, 48, 2341-2348.

37) Moo-Penn, W. F.; Wolff, J. A.; Simon, G.; Vacek, M.; Jue, D. L.;Johnson, M. H. Febs Lett. 1978, 92, 53-56.

38) King, M. A. R.; Willshire, B. G.; Lehmann, H.; Marimoto, H. Br. J.Haem. 1972, 22, 125-134.

39) Ranney, H. M.; Jacobs, A. S.; Nagel, R. L. Nature 1967, 213,876-878.

40) Minnich, V.; Hill, R. J.; Khuri, P. D.; Anderson M. E. Blood 1965,25, 830-838.

41) Ohba, Y.; Miyaji, T.; Murakami, M.; Kadowaki, S.; Fujita, T.;Oimoni, M.; Hatanaka, H.; Ishikawa, K.; Baba, S.; Hitaka, K,; Imai, K.Hemoglobin 1986, 10, 109-126.

                  TABLE 2                                                         ______________________________________                                        Candidate Non-Naturally Occurring Low Affinity                                Hemoglobin Mutants                                                            ______________________________________                                                    alpha chain                                                                   46 phe-->thr                                                                  46 phe-->ser                                                                  46 phe-->ala                                                                  58 his-->phe                                                                  58 his-->trp                                                                  61 lys-->thr                                                                  61 lys-->ser                                                                  61 lys-->met                                                                  61 lys-->asn                                                                  62 val-->leu                                                                  62 val-->ile                                                                  62 val-->phe                                                                  62 val-->trp                                                                  65 ala-->asp                                                                  94 asp-->gln                                                                  94 asp-->thr                                                                  94 asp-->ser                                                                  94 asp-->lys                                                                  94 asp-->gly                                                                  94 asp-->arg                                                                  beta chain                                                                    21 asp-->ala                                                                  21 asp-->ser                                                                  45 phe-->ala                                                                  45 phe-->thr                                                                  45 phe-->val                                                                  63 his-->phe                                                                  63 his-->trp                                                                  66 lys-->ser                                                                  66 lys-->asn                                                                  67 val-->phe                                                                  67 val-->trp                                                                  67 val-->ile                                                                  70 ala-->glu                                                                  70 ala-->ser                                                                  70 ala-->thr                                                                  96 leu-->phe                                                                  96 leu-->his                                                                  96 leu-->lys                                                                  98 val-->trp                                                                  98 val-->phe                                                                  102 asn-->asp                                                                 102 asn-->glu                                                                 102 asn-->arg                                                                 102 asn-->his                                                                 102 asn-->gly                                                                 108 asn-->arg                                                                 108 asn-->glu                                                     ______________________________________                                    

                  TABLE 3                                                         ______________________________________                                        Oxygen Affinity Values for Mutant Hemoglobins                                 Hemoglobin Mutant                                                                          P.sub.50 (mmHg)                                                                          P.sub.50 mutant/P.sub.50 wild type                    ______________________________________                                        Hgb (beta phe.sup.63)                                                                      36.0       7.5                                                   Hgb (beta ile.sup.67)                                                                      9.4        2.0                                                   Hgb (beta thr.sup.102)                                                                     11.1       4.6                                                   ______________________________________                                    

                                      TABLE 4                                     __________________________________________________________________________    Amino Acid Sequence and Helical Residue Notation                              for Human Hemoglobin A.sub.o                                                  ALPHA CHAIN       BETA CHAIN                                                  Helix                                                                             α                                                                            Helix                                                                             α                                                                            Kelix                                                                             β                                                                             Kelix                                                                             β                                         __________________________________________________________________________    NA1  1 Val                                                                             E18  69 Als                                                                            NA1  1 Val                                                                             E18  74 Gly                                                 E19  70 Val                                                                            NA2  2 His                                                                             E19  75 Leu                                        NA2  2 Leu                                                                             E20  71 Ala                                                                            NA3  3 Leu                                                                             E20  76 Ala                                        A1   3 Ser                                                                             EF1  72 His                                                                            A1   4 Thr                                                                             EF1  77 His                                        A2   4 Pro                                                                             EF2  73 Val                                                                            A2   5 Pro                                                                             EF2  78 Leu                                        A3   5 Ala                                                                             EF3  74 Asp                                                                            A3   6 Glu                                                                             EF3  79 Asp                                        A4   6 Asp                                                                             EF4  75 Asp                                                                            A4   7 Glu                                                                             EF4  80 Asn                                        A5   7 Lys                                                                             EF5  76 Met                                                                            A5   8 Lys                                                                             EF5  81 Leu                                        A6   8 Thr                                                                             EF6  77 Pro                                                                            A6   9 Ser                                                                             EF6  82 Lys                                        A7   9 Asn                                                                             EF7  78 Asn                                                                            A7  10 Ala                                                                             EF7  83 Gly                                        A8  10 Val                                                                             EF8  79 Ala                                                                            A8  11 Val                                                                             EF8  84 Thr                                        A9  11 Lys                                                                             F1   80 Leu                                                                            A9  12 Thr                                                                             F1   85 Phe                                        A10 12 Ala                                                                             F2   81 Ser                                                                            A10 13 Ala                                                                             F2   86 Ala                                        A11 13 Ala                                                                             F3   82 Ala                                                                            A11 14 Leu                                                                             F3   87 Thr                                        A12 14 Trp                                                                             F4   83 Leu                                                                            A12 15 Trp                                                                             F4   88 Leu                                        A13 15 Gly                                                                             F5   84 Ser                                                                            A13 16 Gly                                                                             F5   89 Ser                                        A14 16 Lys                                                                             F6   85 Asp                                                                            A14 17 Lys                                                                             F6   90 Glu                                        A15 17 Val                                                                             F7   86 Leu                                                                            A15 18 Val                                                                             F7   91 Leu                                        A16 18 Gly                                                                             F8   87 His       F8   92 His                                        AB1 19 Ala                                                                             F9   88 Ala       F9   93 Cys                                        B1  20 His                                                                             FG1  89 His                                                                            B1  19 Asn                                                                             FG1  94 Asp                                        B2  21 Ala                                                                             FG2  90 Lys                                                                            B2  20 Val                                                                             FG2  95 Lys                                        B3  22 Gly                                                                             FG3  91 Leu                                                                            B3  21 Asp                                                                             FG3  96 Leu                                        B4  23 Glu                                                                             FG4  92 Arg                                                                            B4  22 Glu                                                                             FG4  97 His                                        B5  24 Tyr                                                                             FG5  93 Val                                                                            B5  23 Val                                                                             FG5  98 Val                                        B6  25 Gly                                                                             G1   94 Asp                                                                            B6  24 Gly                                                                             G1   99 Asp                                        B7  26 Ala                                                                             G2   95 Pro                                                                            B7  25 Gly                                                                             G2  100 Pro                                        B8  27 Glu                                                                             G3   96 Val                                                                            B8  26 Glu                                                                             G3  101 Glu                                        B9  28 Ala                                                                             G4   97 Asn                                                                            B9  27 Ala                                                                             G4  102 Asn                                        B10 29 Leu                                                                             G5   98 Phe                                                                            B10 28 Leu                                                                             G5  103 Phe                                        B11 30 Glu                                                                             G6   99 Lys                                                                            B11 29 Gly                                                                             G6  104 Arg                                        B12 31 Arg                                                                             G7  100 Leu                                                                            B12 30 Arg                                                                             G7  105 Leu                                        B13 32 Met                                                                             G8  101 Leu                                                                            B13 31 Leu                                                                             G8  106 Leu                                        B14 33 Phe                                                                             G9  102 Ser                                                                            B14 32 Leu                                                                             G9  107 Gly                                        B15 34 Leu                                                                             G10 103 His                                                                            B15 33 Val                                                                             G10 108 Asn                                        B16 35 Ser                                                                             G11 104 Cys                                                                            B16 34 Val                                                                             G11 109 Val                                        C1  36 Phe                                                                             G12 105 Leu                                                                            C1  35 Tyr                                                                             G12 110 Leu                                        C2  37 Pro                                                                             G13 106 Leu                                                                            C2  36 Pro                                                                             G13 111 Val                                        C3  38 Thr                                                                             G14 107 Val                                                                            C3  37 Trp                                                                             G14 112 Cys                                        C4  39 Thr                                                                             G15 108 Thr                                                                            C4  38 Thr                                                                             G15 113 Val                                        C5  40 Lys                                                                             G16 109 Leu                                                                            C5  39 Gln                                                                             G16 114 Leu                                        C6  41 Thr                                                                             G17 110 Ala                                                                            C6  40 Arg                                                                             G17 115 Ala                                        C7  42 Tyr                                                                             G18 111 Ala                                                                            C7  41 Phe                                                                             G18 116 His                                        CE1 43 Phe                                                                             G19 112 His                                                                            CD1 42 Phe                                                                             G19 117 His                                        CE2 44 Pro                                                                             GH1 113 Leu                                                                            CD2 43 Glu                                                                             GH1 118 Phe                                        CE3 45 His                                                                             GH2 114 Pro                                                                            CD3 44 Ser                                                                             GH2 119 Gly                                        CE4 46 Phe                                                                             GH3 115 Ala                                                                            CD4 45 Phe                                                                             GH3 120 Lys                                                 GH4 116 Glu                                                                            CD5 46 Gly                                                                             GH4 121 Glu                                        CE5 47 Asp                                                                             GH5 117 Phe                                                                            CD6 47 Asp                                                                             GH5 122 Thr                                        CE6 48 Leu                                                                             H1  118 Thr                                                                            CD7 48 Leu                                                                             H1  123 Thr                                        CE7 49 Ser                                                                             H2  119 Pro                                                                            CD8 49 Ser                                                                             H2  124 Pro                                        CE8 50 His                                                                             H3  120 Ala                                                                            D1  50 Thr                                                                             H3  125 Pro                                                 H4  121 Val                                                                            D2  51 Pro                                                                             H4  126 Val                                                 H5  122 His                                                                            D3  52 Asp                                                                             H5  127 Gln                                                 H6  123 Ala                                                                            D4  53 Ala                                                                             H6  128 Ala                                                 H7  124 Ser                                                                            D5  54 Val                                                                             H7  129 Ala                                                 H8  125 Leu                                                                            D6  55 Met                                                                             H8  130 Tyr                                        CE9 51 Gly                                                                             H9  126 Asp                                                                            D7  56 Gly                                                                             H9  131 Gln                                        E1  52 Ser                                                                             H10 127 Lys                                                                            E1  57 Asn                                                                             H10 132 Lys                                        E2  53 Ala                                                                             H11 128 Phe                                                                            E2  58 Pro                                                                             H11 133 Val                                        E3  54 Gln                                                                             H12 129 Leu                                                                            E3  59 Lys                                                                             H12 134 Val                                        E4  55 Val                                                                             H13 130 Ala                                                                            E4  60 Val                                                                             H13 135 Ala                                        E5  56 Lys                                                                             H14 131 Ser                                                                            E5  61 Lys                                                                             H14 136 Gly                                        E6  57 Gly                                                                             H15 132 Val                                                                            E6  62 Ala                                                                             H15 137 Val                                        E7  58 His                                                                             H16 133 Ser                                                                            E7  63 His                                                                             H16 138 Ala                                        E8  59 Gly                                                                             H17 134 Thr                                                                            E8  64 Gky                                                                             H17 139 Asn                                        E9  60 Lys                                                                             H18 135 Val                                                                            E9  65 Lys                                                                             H18 140 Ala                                        E10 61 Lys                                                                             H19 136 Leu                                                                            E10 66 Lys                                                                             H19 141 Leu                                        E11 62 Val                                                                             H20 137 Thr                                                                            E11 67 Val                                                                             H20 142 Ala                                        E12 63 Ala                                                                             H21 138 Ser                                                                            E12 68 Leu                                                                             H21 143 His                                        E13 64 Asp                                                                             HC1 130 Lys                                                                            E13 69 Gly                                                                             HC1 144 Lys                                        E14 65 Ala                                                                             HC2 140 Tyr                                                                            E14 70 Ala                                                                             HC2 145 Tyr                                        E15 66 Leu                                                                             HC3 141 Arg                                                                            E15 71 Phe                                                                             HC3 146 His                                        E16 67 Thr        E16 72 Ser                                                  E17 68 Asn        E17 73 Asp                                                  __________________________________________________________________________

                                      TABLE 5                                     __________________________________________________________________________    OLIGONUCLEOTIDES USED TO MUTAGENIZE THE                                       ALPHA AND BETA GENES                                                          Name    Sequence (5' . . . 3')                                                __________________________________________________________________________    94α Sense                                                                       5'                                                                              CGCGTTGTCTGCTCTGTCTGATCTGCACGCTCACAAAC                                        TGCGTGTTTGCCCGGTT 3'                                                94α Antisense                                                                   5'                                                                              AACCGGGCAAACACGCAGTTTGTGAGCGTGCAGATCAGA                                       CAGAGCAGACAA 3'                                                     97β Sense                                                                        5'                                                                              CCACTGCGACAAACTGTGCGTTGACCCGGAAAACTTCCG                                       TCTGCTGGGTAACGTA 3'                                                 97β Antisense                                                                    5'                                                                              CTAGTACGTTACCCAGCAGACGGAAGTTTTCCGGGTCAA                                       CGCACAGTTTGTCGCAGTGGAGCT                                            99β Sense                                                                        5'                                                                              CCACTGCGACAAACTGCACGTTTGCCCGGAAAACTTCCG                                       TCTGCTGGGTAACGTA 3'                                                 99β Antisense                                                                    5'                                                                              CTAGTACGTTACCCAGCAGACGGAAGTTTTCCGGGCAAA                                       CGTGCAGTTTGTCGCAGTGGAGCT 3'                                         101β Sense                                                                       5'                                                                              CCACTGCGACAAACTGCACGTTGACCCGTGCAACTTCCG                                       TCTGCTGGGTAACGTA 3'                                                 101β Antisense                                                                   5'                                                                              CTAGTACGTTACCCAGCAGTCGGAAGTTGCACGGGTCAA                                       CGTGCAGTTTGTCGCAGTGGAGCT 3'                                         __________________________________________________________________________

                  TABLE 6                                                         ______________________________________                                        PRIMERS USED FOR THE SEQUENCING                                               OF α AND β GENES                                                   Name        Length  Sequence (5' . . . 3')                                    ______________________________________                                        Universal Primer                                                                          17mer   GTAAAACGACGGCCAGT                                         Reverse Universal                                                                         16mer   AACAGCTATGACCATG                                          Primer                                                                        Primer No. 2                                                                              18mer   TGGCTTCTGTTTCTACCG                                        Primer No. 3                                                                              18mer   TTTCTCTGACGGTCTGGC                                        Reverse Primer                                                                            18mer   CAGACCGTCAGAGAAAGC                                        No. 2                                                                         Reverse Primer                                                                            18mer   GTAGAAACAGAAGCCAGG                                        No. 3                                                                         ______________________________________                                    

We claim:
 1. A non-naturally occurring hemoglobin-like protein whichfinds oxygen, said protein comprising at least one tetramer orpseudotetramer of two alpha globin-like subunits and two betaglobin-like subunits, where a cysteine of a first alpha globin-likesubunit is covalently linked to a cysteine of a second alpha or betaglobin-like subunit by an intratetramer, intersubunit disulfide bond,wherein at least one of said cysteines is a substitution for anon-cysteine amino acid residue in the corresponding subunit ofconventional hemoglobin.
 2. The protein of claim 1 wherein bothcysteines are substituted for non-cystein amino acid residue in thecorresponding subunit of conventional hemoglobin.
 3. The protein ofclaim 1 wherein an alpha globin-like subunit is linked to a betaglobin-like subunit.
 4. The protein of claim 1 wherein the disulfidebond crosses the alpha₁ /beta₂ or alpha₂ /beta₁ intersubunit interface.5. The protein of claim 2 wherein, when the disulfide bridge connectstwo alpha globin-like subunits, it does not connect the residuescorresponding to Lys99 in alpha globin.
 6. The protein of claim 1 whichcomprises two identical disulfide bonds.
 7. The protein of claim 1wherein one of said cysteines is a substitution for a non-cysteine aminoacid residue in the alpha globin subunit.
 8. The protein of claim 6wherein one of said cysteines is a substitution for a non-cysteine aminoacid residue in the alpha globin subunit.
 9. The protein of claim 1wherein, when a first cysteine of an alpha globin like subunit iscovalently linked to another cysteine, said first cysteine is selectedfrom the group consisting of cysteine residues essentially correspondingto residues 41, 44, 92, 94 and 96 of alpha globin, and wherein, where afirst cysteine of a beta globin like subunit is covalently linked toanother cysteine, said first cysteine is selected from the groupconsisting of residues essentially corresponding to residues 37, 40, 97,99 and 101 of beta globin.
 10. The protein of claim 2 wherein thedisulfide bridge connects two alpha globin-like subunits.
 11. Theprotein of claim 2, wherein the cysteine substitutions are selected fromthe group consisting of:i) Codon 41alpha Thr(ACC) →Cys (TGC) Codon99beta Asp (GAC) →Cys (TGC) ii) Codon 44alpha Pro (CCG) →Cys (TGC) Codon97beta His (CAC) →Cys (TGC) iii) Codon 94alpha Asp(GAT) →Cys (TGC) Codon101beta Glu (GAA) →Cys (TGC) iv) Codon 41alpha Thr (ACC) →Cys (TGC)Codon 97beta His (CAC) →Cys (TGC) v) Codon 92alpha Arg(CGT) →Cys (TGC)Codon 37beta Trp (CAC) →Cys (TGC) vi) Codon 92alpha Arg (CGT) →Cys (TGC)Codon 40beta Arg (CGT) →Cys (TGC) vii) Codon 96alpha Val (GTT) →Cys(TGC) Codon 101beta Glu (GAA) →Cys (TGC).
 12. The protein of claim 1,characterized by a more stable T state than that of conventionalhemoglobin.
 13. A pharmaceutical composition comprising the protein ofclaim 1 in a pharmaceutically acceptable carrier.
 14. The protein ofclaim 1 which is sufficiently soluble in human blood under physiologicalconditions to be useful as a blood substitute.
 15. The protein of claim1 which has a P₅₀ which is at least 10% greater than that ofconventional hemoglobin under the same conditions.
 16. The protein ofclaim 1 which comprises only one tetramer or pseudotetramer ofglobin-like subunits.
 17. The protein of claim 1 which ispharmaceutically acceptable.